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ABSTRACT 
 
Urinary tract infections (UTIs) are one of the most common healthcare-associated 
infections (HAIs), including in long and medium-term healthcare facilities (LMTHF), 
situated at the interface of the hospital and the community settings. In this setting 
(LMTHF), UTIs are an increasing challenge due to the high occurrence rates, the frequent 
resident’s comorbidities, the diversity of etiologic agents and the diagnostic difficulties. 
Furthermore, the emergence of resistance to critically important antibiotics restricts the 
available therapeutic options to treat UTIs and determines the need of monitoring etiologic 
agents and antibiotic resistance profiles in order to improve diagnosis, treatment and 
prevention. However, in Portugal, scarce data on the species and antimicrobial 
susceptibility of bacterial pathogens responsible for UTI in LMTHF is available.  
The aim of the present study was to evaluate the trends of etiologic agents of UTIs and 
their antimicrobial resistance patterns in patients of a LMTHF, in the North of Portugal, 
between november 2010 and august 2015. 
A total of 691 urine samples were retrospectively analyzed, from which 471 urine samples 
(68.2%) were positive for bacterial growth, where 512 uropathogens were identified. 
Escherichia coli was the most common species (38.5%), followed by Klebsiella 
pneumoniae (26.8%), Proteus spp. (8.6%) and Pseudomonas aeruginosa (7.2%), whilst 
Enterococcus faecalis (4.3%) was the most frequent Gram-positive species. Multi-drug 
resistance patterns were frequently observed (n=242/512; 47.3%), with the highest rates 
registered for K. pneumoniae (59.1%). The highest antimicrobial resistance rates were 
observed for penicillins (61.4%-97.5%), followed by fluoroquinolones (43.5%-55.0%) and 
trimethoprim/sulfamethoxazole (49.6%). On the other hand, nitrofurantoin, cefoxitin, 
amikacin, piperacillin/tazobactam, carbapenems and glycopeptides were the most active 
antibiotics (2.0%-10.0%). Amongst the most frequent uropathogens identified (E. coli and 
K. pneumoniae), the antibiotic resistance rates to extended-spectrum cephalosporins, 
trimethoprim/sulfamethoxazole and ciprofloxacin increased substantially, especially after 
2011, whereas imipenem, nitrofurantoin and fosfomycin remained stable during the whole 
period studied (<6.0%). Extended spectrum β-lactamase (ESBL) producers were detected 
in 24.1% (n=101/419) of Enterobacteriaceae isolates, being of note the recent increase of 
ESBL-producing K. pneumoniae (reaching 72.2% in 2015). Two ESBL-producing K. 
pneumoniae strains were simultaneously carbapenemase-producers (KPC-type). 
Statistically significant differences were not observed between gender and incidence of 
ESBL-producing strains (P=0.524). 
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The general conclusion: This study alerts for the increasing rates of multidrug resistance 
among urinary pathogens causing UTIs in patients institutionalized in a LMTHF in 
Portugal, and highlights the need to adapt empirical treatment choices and infection 
control practices to local data. 
 
KEYWORDS: Antimicrobial Resistance, Extended-spectrum β-lactamases, Multi-drug 
Resistance, Uropathogens 
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RESUMO 
 
As infeções do trato urinário (UTIs) são uma das principais infeções associadas aos 
cuidados de saúde (HAIs), incluindo as unidades de cuidados de saúde de longa e média 
duração (LMTHF), caracterizadas como a interface entre o ambiente hospitalar e a 
comunidade. Neste ambiente (LMTHF), as UTIs são um desafio crescente devido às 
elevadas taxas de ocorrência, às frequentes comorbilidades associadas aos residentes, à 
diversidade de agentes etiológicos e às dificuldades de diagnóstico. Além disso, a 
emergência de resistência aos antibióticos criticamente importantes limita as opções 
terapêuticas disponíveis para o tratamento de UTIs e determina a necessidade de 
monitorizar os agentes etiológicos e os perfis de resistência aos antibióticos para 
melhorar o diagnóstico, o tratamento e a prevenção. No entanto, em Portugal, os dados 
sobre as espécies e suscetibilidade aos antimicrobianos das bactérias responsáveis 
pelas UTIs em LMTHF é escassa. 
O objetivo do presente estudo foi avaliar as tendências dos agentes etiológicos das UTIs 
e seus padrões de resistência aos antimicrobianos em doentes de um LMTHF, no Norte 
de Portugal, entre novembro de 2010 e agosto de 2015. 
Um total de 691 amostras de urina foram analisadas retrospetivamente, das quais 471 
(68,2%) foram positivas para crescimento bacteriano, tendo sido identificados 512 
patogénicos urinários. E. coli foi a espécie mais comum (38,5%), seguida de K. 
pneumoniae (26,8%), Proteus spp. (8,6%) e Pseudomonas aeruginosa (7,2%), enquanto 
Enterococcus faecalis (4,3%) foi a espécie Gram-positiva mais frequente. Padrões de 
resistência a múltiplos antibióticos foram observados frequentemente (n=242/512; 
47,3%), com elevadas taxas registadas para K. pneumoniae (59,1%). As taxas de 
resistência aos antimicrobianos mais elevadas foram observadas para as penicilinas 
(61,4%-97,5%), seguidas pelas fluoroquinolonas (43,5%-55,0%) e 
trimetoprim/sulfametoxazol (49,6%). Por outro lado, a nitrofurantoína, cefoxitina, 
amicacina, piperacilina/tazobactam, carbapenemos e glicopéptidos foram os antibióticos 
mais ativos (2,0%-10,0%). Entre os uropatogénicos mais frequentemente identificados (E. 
coli e K. pneumoniae), as taxas de resistência aos antibióticos para as cefalosporinas de 
largo espetro, trimetoprim/sulfametoxazol e ciprofloxacina aumentaram substancialmente, 
especialmente depois de 2011, ao passo que o imipenem, a nitrofurantoína e a 
fosfomicina mantiveram-se estáveis durante todo o período estudado (<6,0%). β-
lactamases de espetro alargado (ESBL) foram detetadas em 24,1% (n=101/419) dos 
isolados de Enterobacteriaceae, salientando o recente aumento de K. pneumoniae 
produtoras de ESBLs (atingindo 72,2% em 2015). Duas estirpes de K. pneumoniae 
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produtoras de ESBLs foram simultaneamente produtoras de carbapenemases do tipo 
KPC. Estatisticamente não foram observadas diferenças significativas entre género e 
incidência de estirpes produtoras de ESBLs (P=0,524). 
A conclusão geral: Este estudo alerta para o aumento das taxas de multirresistência 
entre os patogénicos urinários que causam UTIs em doentes institucionalizados de uma 
LMTHF em Portugal, e destaca a necessidade de ajustar as opções terapêuticas para o 
tratamento empírico e as práticas de controlo de infeção, de acordo com os dados locais. 
 
PALAVRAS-CHAVE: Resistência aos antimicrobianos, β-lactamases de espetro alargado, 
Resistência a múltiplos antibióticos, Uropatogénicos 
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1.1. CHARACTERIZATION OF LONG AND MEDIUM-TERM HEALTHCARE FACILITIES 
The long and medium-term healthcare facilities (LMTHF) are an intermediate setting 
between community and hospital setting (1, 2). These healthcare facilities are part of a 
national network of continuing healthcare created by legal rule n.º 101/2006 of June 6, 
with the main aims: rehabilitation, readaptation, social integration and maintenance of life 
quality, even in irreversible health conditions (3, 4). This national network is coordinated 
by central (Central Administration of Health System), regional and local team, involving 
health professionals (doctors, nurses), social assistants and elements of local authorities 
(5). 
In Portugal, the provisions of continuing healthcare facilities ensured by inpatient units 
have some typologies: 
a) Palliative healthcare; 
b) Convalescence healthcare: these units have the finality to internment with 
predictability until thirty consecutive days; 
c) Medium-term healthcare: these units have the finality to clinical stabilization, 
evaluation and integral rehabilitation of the patient, for a period greater than 30 
and less than 90 consecutive days; 
d) Long-term healthcare: these units were created to provide support to patients with 
chronic diseases, preventing the deterioration of health status and promoting the 
life quality, for an internment period higher ninety days (1, 3, 6). 
Most countries have separate long-term healthcare facilities (LTHFs) for elderly (e.g. 
residential homes, nursing homes), physically disabled (sometimes younger population), 
mentally disabled and psychiatric care. In other countries, mixed LTHFs are the standard 
(7).  
In Portugal, the majority is mixed LTHFs (54.5%), and the remaining is rehabilitation 
centers (45.5%) (7). The majority of LTHFs are private institutions of social solidarity 
(IPSS), such as Santa Casa da Misericórdia (54%), other IPSS (23%), private institutions 
for profit (18%) or health national service (HNS, 5%). The agreements with the HNS 
decreased 42%. Regarding the demographic characterization, the resident population 
aged over 65 and 80 year represent 84.5% and 47% of the total, respectively. The female 
gender corresponded 55.7% of a total resident; 50% of residents were women over the 
age of 65 and 30.4% of residents were women over the age of 80. The men in this age 
group represent 16.6% (5). 
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Medical residential care in national LTHFs are mainly provided by employed medical staff 
(91.8%), and the remaining by general practitioners (GPs) visiting the LTHFs (1.4%). This 
trend is not observed in European countries, where 58.5% of medical care are provided 
by GPs visiting the LTHF (7). According to the last report (first semester of 2015) on 
national continuing healthcare network, were identified 4222 beds for long-term, 2087 
beds in medium-term, 750 beds for convalescence, and 252 beds for palliative care (8). 
The median size of LTHFs was 23 beds, lower relatively the European median (64 beds). 
The median percentage of single rooms was 22.2% for a European median of 57.1% (7).   
Several LMTHF aspects enhance the possibility of infection acquisition and limit the 
effectiveness of infection control measures. Among them, are: 
a) Continuous flow of residents with several comorbidities in and out of the facility 
frequently to and from acute care settings increase the risk of infection (1, 2). 
b) Residents exposition to high antibiotic pressure with frequent antibiotic prescription 
without the presence of infection (2). 
c) The confluence of a) and b) together with the entrance of residents colonized with 
multi-drug resistant (MDR) strains acquired in the acute setting (2, 9) turns these 
settings as important reservoirs of MDR bacteria (10).  
d) Social sharing/interaction and close proximity between patients of LMTHF favors 
the acquisition of microorganisms, thus increasing the risk of infection and 
admission in acute care hospitals (1, 2). 
It is recognized that these factors increase the risk of infection acquisition by LMTHF 
residents, and particularly for older residents (4, 7, 8). 
Comparatively with European crude prevalence of residents with at least one HAI (3.4%), 
the national LTHFs obtained the greater prevalence (9.5%). The median prevalence in 
LTHFs ranged from 0.4% in Croatia to 7.1% in Portugal. The European countries with 
prevalence more close to Portugal were UK-Northern Ireland (6.9%) and Netherlands 
(5.8%) (7); however, these facilities could be highly diverse, as they can care residents 
with a broad range of chronic and acute diseases, from different ages, varying in the 
number and type of invasive procedures which difficult comparisons (7).  
From a national point prevalence survey of HAIs and antimicrobial use (2013), conducted 
in 143 continuing healthcare facilities (49.9% long-term, 29.3% medium-term, 17.4% 
convalescence and 3.4% palliative healthcare) were identified the resident’s most 
important characteristics, including risk factors for HAIs, such as impaired mobility (73-
CHAPTER 1 - INTRODUCTION  
5 
 
78.3%), incontinence (60.4-79.4%), disorientation (40.7-62%), more than 85 years (20.6-
27.3%), pressure sores (13.4-21.7%) and urinary catheter (14.6-17.3%) (5).  
The continuing healthcare facility of Santa Casa da Misericórdia de Vila do Conde is 
composed by both, long and medium-term healthcare, which include 15 and 25 beds, 
respectively, with an overall capacity for 40 patients. The population admitted in both 
typologies were a majority from the area of Porto district (Porto, Maia, Vila Nova de Gaia, 
Matosinhos, Vila do Conde, Póvoa de Varzim, Gondomar, Trofa, Vila Nova de 
Famalicão), and others districts of north (e.g. Viana do Castelo, Braga, Aveiro). However, 
the units can admit patients of different geographic area of Portugal. These patients were 
referenced from district/ local hospitals and health centers for these units.  
In both, long and medium-term, the patients were mostly female and older, with mean age 
of 75 ± 12 years (median 78 years). The main comorbidities identified in LTHF were 
ischemic stroke, following by disuse syndrome, fracture, hemorrhagic stroke, head 
trauma. In medium-term healthcare the most frequent comorbidities observed were 
ischemic stroke, following by disuse syndrome, hemorrhagic stroke and tetraparesis. 
The LMTHF are composed by infection prevention and control (IPC) committee, and the 
medical resident care and nursing staff have clinical training in IPC, and access to IPC 
advice. It was implemented hand hygiene protocol, and the hand disinfection is performed 
using an alcohol-based solution. It was also, implemented a restrictive list of 
antimicrobials for prescription, excluding carbapenems, glycopeptides and the 
intravenously administered antibiotics (exceptional use). 
 
1.2. URINARY TRACT INFECTIONS 
Despite the recent description of a normal bladder microbiota and the recognized 
limitations on the current diagnosis process of urinary pathologies, still there is no new 
recommendations for UTI diagnosis (11, 12). Future studies will contribute to understand 
microbiota in relation to urological diseases (e.g. overactive bladder syndrome, urge 
urinary incontinence (UUI), interstitial cystitis, neurogenic bladder dysfunction, 
asymptomatic bacteriuria (ASB) and UTI) and may help to clarify on the pathogenesis of 
these dysfunctions, it might also change how we diagnose, treat and prevent UTI. 
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1.2.1.  CLASSIFICATION OF URINARY TRACT INFECTION 
UTI is defined as an infection of the urinary system, and may involve the lower urinary 
tract or both, the lower and upper urinary tracts (13-16).  
Traditionally, UTIs are classified based on clinical symptoms, laboratory data and 
microbiological findings (17), being subclassified into complicated and uncomplicated, 
(Table 1) and sepsis. The first requires that the urinary tract has a structural or functional 
abnormality and includes all upper UTIs (18), but the seconds occurring in a structurally 
normal urinary tract (17, 19-21).  
TABLE 1 - Definition of common terms [readapted from reference (19)]. 
Pyuria > 10 white blood cells (WBC)/mm
3 
per high-power field 
ASB Bacteriuria in the absence of genitourinary signs or symptoms 
Symptomatic UTI 
Bacteriuria in the presence of genitourinary symptoms (e.g. dysuria, suprapubic pain 
or tenderness, frequency or urgency) 
Uncomplicated UTI 
Genitourinary symptoms (e.g. dysuria, suprapubic pain or tenderness, frequency or 
urgency) with evidence of pyuria plus bacteriuria in a structurally normal urinary tract 
Complicated UTI UTI occurring in a patient with a structural or functional urinary tract abnormality 
 
The guidelines on urological infections of European Association of Urology (2015) cover 
UTIs and male accessory gland infections  because both infections are closely associated 
in males (Table 2) (17).  
TABLE 2 - Classification of urinary tract and male genital infections [readapted from reference (17)]. 
Uncomplicated lower UTI: Cystitis (acute, sporadic or recurrent) 
Uncomplicated upper UTI: Pyelonephritis (acute, sporadic, no risk factor identified) 
Complicated UTI with or without pyelonephritis (acute, sporadic, no risk factor identified) 
Urosepsis: Systemic inflammatory response syndrome (fever or hypothermia, hyperleukocytosis or leucopenia, 
tachycardia, tachypnea) 
Urethritis: Poorly understood besides sexually transmitted conditions 
Male accessory gland infections: Prostatitis, epididymitis, orchitis 
 
Thus, the guidelines of European Association of Urology (2015) classified the UTIs based 
on anatomical level of infection, grade of severity of infection, underlying risk factors and 
microbiological findings. The symptoms, signs and laboratory finding focus on the 
anatomical level of infection, defined the UTIs as: 
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a) Urethra: urethritis; 
b) Bladder: cystitis; 
c) Kidney: pyelonephritis; 
d) Bloodstream: sepsis (17). 
The clinical and laboratorial criteria for classification of UTIs are listed in Table 3: 
TABLE 3 - Criteria for the diagnosis of urinary tract infections, as modified according to Infectious Disease 
Society of America /European Society of Clinical Microbiology and Infectious Diseases guidelines [readapted 
from reference (17)]. 
Category Description Clinical features Laboratory investigations 
1 Asymptomatic bacteriuria No urinary symptoms 
> 10 WBC/mm
3 
> 10
5 
CFU/ml in two 
consecutive midstream urine 
cultures in women or one urine 
culture in men 
> 24 h apart 
2 
Acute uncomplicated UTI in 
women; acute uncomplicated 
cystitis in women 
Dysuria, urgency, frequency, 
suprapubic pain, no urinary 
symptoms in 4 weeks before this 
episode 
> 10 WBC/mm3 
> 10
3
 CFU/ml in midstream 
urine culture 
3 
Acute uncomplicated 
pyelonephritis 
Fever, chills, flank pain; other 
diagnoses exclude; no history or 
clinical evidence of urological 
abnormalities (ultrasonography 
radiography) 
> 10 WBC/mm3 
> 10
4
 CFU/ml in midstream 
urine culture 
4 Complicated UTI 
Any combination of symptoms from 
categories 1 and 2 above; one or 
more factors associated with a 
complicated UTI 
> 10 WBC/mm3 
> 10
5
 CFU/ml in women 
> 10
4
 CFU/ml in men, or in 
straight catheter urine in 
women 
5 
Recurrent UTI (antimicrobial 
prophylaxis) 
At least three episodes of 
uncomplicated infection documented 
by culture in past 12 months: women 
only; no structural/functional 
abnormalities 
< 10
3
 CFU/ml in midstream 
urine culture 
In a suprapubic bladder puncture specimen, any count of bacteria is relevant 
 
1.2.2. DIAGNOSIS OF URINARY TRACT INFECTIONS IN LONG AND MEDIUM-TERM 
HEALTHCARE FACILITIES 
The symptoms of UTI in community-dwelling older adults are well defined and include 
urethritis (hematuria and dysuria), cystitis (urethritis with frequency, urgency and 
suprapubic pain), and pyelonephritis (fever, nausea/emesis, flank pain preceded or not by 
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urethritis/cystitis); however, there is no consensus about symptoms that better reflecting 
an UTI in LMTHF residents (22, 23).  
In LMTHF, it is particularly important to differentiate symptomatic UTI from ASB (13), as 
current guidelines do not recommend screening or treatment of ASB for the following 
groups of older adults: institutionalized adults, patients with an indwelling urinary catheter, 
or individuals living in the community (13, 19). Screening and treatment of ASB is only 
recommended in older adult men undergoing a resection of the prostate and in any 
urologic procedure in which mucosal bleeding is anticipated or in pregnant (13, 17, 19, 
56). 
The diagnosis of UTI in LMTHF residents have some challenges such as communication 
barriers (stroke and dementia), high prevalence of chronic genitourinary symptoms 
(urgency, frequency, nocturia, incontinence), and absence of a gold-standard laboratory 
test (bacteriuria with pyuria is common in asymptomatic LMTHF residents) to confirm 
clinical suspicion of UTI due to the high prevalence of ASB (22). 
McGeer et al. (1991) issued the first guidelines for diagnosis of UTIs in LMTHF. These 
criteria are considered as the standard for diagnosis and treatment of UTI, and included 
fever (≥ 38ºC) or chills, dysuria, frequency or urinary urgency, suprapubic or flank pain, 
change in urine character, degradation of mental or functional status, or new increased 
incontinence. These criteria divided the symptoms into major and minor and reinforce the 
laboratorial confirmation (19, 22). 
In 2005, Loeb et al. adapted these criteria with aim to reduce the use of antibiotics to treat 
UTI in LMTHF residents (Table 4) (19, 22).  
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TABLE 4 - Consensus criteria for diagnosis of urinary tract infections in long-term care residents [reprinted from 
reference (22)]. 
 
 
Both guidelines have demonstrated low accuracy in predicting bacteriuria and pyuria, 
which constitute analytical evidence of UTI. The McGeer criteria had a sensitivity of 30%, 
a specificity of 82%, a positive predictive value (PPV) of 57%, and a negative predictive 
value (NPV) of 61%; the accuracy of the modified Loeb criteria was 30%, 79%, 52% and 
60%, respectively (22).  
Rowe et al. proposed an algorithm based on the revised McGeer criteria, with additional 
suggestions based on adding empirically derived criteria (Figure 1) (19). 
 
CHAPTER 1 - INTRODUCTION  
 
10 
 
 
FIGURE 1 - Diagnostic algorithm for urinary tract infection in long-term care facilities in residents without an 
indwelling catheter [adapted from reference (13)]. 
† Change in color or odor of urine. 
‡ Change in level of consciousness, periods of altered perception, disorganized speech or lethargy. 
§ Single temperature ≥37.8ºC (>100ºF) or > 37.2ºC (>99ºF) on repeated occasions, or an increase of > 1.1ºC (>2C) over 
baseline. 
¶ Leukocytosis: > 14,000 cells/mm
3 
or left shift >6% or 1500 bands/mm
3
. WBC: White blood cell. 
 
1.2.2.1. LABORATORY CONFIRMATION 
Bacteriuria and pyuria in urine specimen of LMTHF residents is insufficient to confirm a 
diagnosis of clinically suspected UTI (13, 22). Both conditions are present in 
approximately half of residents without a catheter and in most residents with catheter (22). 
Based to the Infectious Disease Society of America guidelines, in case of suspected UTI 
the initial evaluation should include urinalysis for determination of leukocyte esterase and 
nitrite level by use of dipstick (13). Juthani-Mehta et al. demonstrated a NPV of 100% but 
a PPV of 45% with this method (22). Sundvall and Gunnarsson et al. evaluated the 
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predictive value of combined nitrite and leucocyte esterase dipstick analysis in predicting 
the presence of urinary pathogen in older nursing home residents, and the NPV obtained 
was 88% and PPV was 51% (Figure 2) (18, 19). 
 
 
FIGURE 2 - Negative predictive value and positive predictive value for dipstick urine testing for diagnosis of 
bacteriuria in a nursing home population. Test characteristics of a positive leukocyte esterase and/or a positive nitrite 
dipstick were compared to urine culture. These results were for visual reading of the dipstick; results with analyzer reading 
were almost identical [reprinted from reference (18)]. 
 
Therefore, if the urinary dipstick is negative for leukocyte esterase and nitrite, the 
evaluation can be suspended. If pyuria or a positive leukocyte esterase or nitrite results is 
present, a urine culture should be obtained and, if positive, proceed to antimicrobial 
susceptibility testing (13, 19, 22). 
 
1.2.3. OCCURRENCE OF URINARY TRACT INFECTIONS IN LONG-TERM HEALTHCARE    
FACILITIES RESIDENTS 
The UTIs are the most common infections in LMTHF (8, 9, 11-17), and the main cause of 
hospitalization of residents (4, 11), affecting principally the older resident’s (8-10). 
According to a national point prevalence survey in continuing healthcare facilities, during 
2013, the UTIs were the most common infections (17.5% confirmed and 20% probable 
UTIs), followed by skin and soft tissue infections (26.2%) and respiratory tract infections 
(21.2%) (2), confirming previous findings (2, 10).  
However, in a national point prevalence survey on Portuguese hospitals (2013) the 
respiratory infections (29.3%) were the most frequently, followed by UTIs (21.1%) (24). 
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These findings support previous studies that claim that in hospitalized patients and 
community-dwelling adults over the age of 65 years the UTIs are the second most 
common diagnosed infection (13, 19).  
The incidence and prevalence of UTI varies with age and gender, being higher in women 
than men for all age groups (13). Is frequent in young sexually active women (0.5-0.7 per 
person-year), while in young men (0.01 per person-year) the incidence in lower. However, 
increases substantially with age in both genders (13). In a cohort study, the prevalence of 
UTI in community-dwelling women older than 65 years was approximately 16.5% over a 
6-month period. For men aged 65-74 years, the incidence of UTI increases 0.05 per 
person-year. In both women and men older than 85 years, the incidence of UTI increases 
significantly (13), with almost 30% of women older than 85 years reporting at least one 
UTI within a 12-month period (19). 
The ASB, a particular entity of UTI (17),  is more common between older adults than in 
younger adults. The prevalence increases significantly with age in both men and women 
(13, 19). The prevalence of ASB is 1-5% in healthy premenopausal women (17), and is  
estimated between 6% to 10% in women older than 60 years and 5% in men older than 
65 years; however, in institutionalized adults, the incidence of ASB is higher, with 
estimates ranging from 25% to 50% for women and 15% to 35% for men (19). In spinal 
cord injury patients a incidence of 23-89% was reported (17). 
 
1.2.4. RISK FACTORS FAVORING URINARY TRACT INFECTIONS IN LONG-TERM 
HEALTHCARE FACILITIES RESIDENTS 
The resident’s population of LMTHF feature numerous medical comorbidities such as 
diabetes, spinal cord injury, stroke, cognitive deficits, urinary/faecal incontinence (13, 25, 
26) and risk factors, including advanced age, impaired mobility, chronic illness, 
immunosuppression (1, 27), urinary catheter (1, 28, 29) and dysbiosis (11), that increases 
the predisposition to UTIs and ASB (13, 22, 27) and colonization with MDR strains during 
residence (2, 22).The most relevant of these risk factors are detailed below: 
a) Impaired mobility in aging adults has been shown to increase the risk of 
hospitalization in case of UTI. A retrospective cohort study (2008) conducted in 
adults older than 65 years admitted in a LTHF observed that who were able to 
walk independently had a 69% reduction in risk of hospitalization for UTI in 
comparison with older adults who did not walk or required significant assistance. 
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These results suggest that maintaining or improving mobility in older adults may 
protect against hospitalization for UTI (19). 
 
b) Alterations in the urinary microbiota linked to urologic disease, such as UUI, 
interstitial cystitis and neurogenic bladder dysfunction were recently suggested 
with the observation of species strongly associated to UUI, such as Aerococcus 
urinae, Gardenerella vaginalis and Lactobacillus gasseri,  that were absent groups 
of other ages (11). 
 
c) Urinary incontinence is the most common urologic conditions in the older 
population (30). An estimated 15%-35% of community-dwelling older people and 
50% of institutionalized people have severe urinary incontinence. The overall 
prevalence increases with age in both women and men (30). Consequently, these 
settings are using more indwelling devices and parenteral antibiotics, exposing the 
patients to MDR bacteria (22).  
 
d) Urinary catheterization is the main risk factor associated with UTI and ASB (13, 
31-34) because disrupts defense mechanisms, promoting the easier access of 
bacteria to the bladder (22), causing bacterial colonization (33), recurrent UTIs 
(rUTIs) and chronic infections, bladder stones and septicaemia, and the 
development of antibiotic resistance (35).  
The urinary catheter use in acute healthcare facilities is usually for short-term, 
while long-term catheters are most common for residents of LTHF (19). A sessile 
bacterial growth (biofilm) occurs frequently in these devices (18, 29), increasing 
the risk of development of bacteriuria time-dependent of catheterization (22, 29), 
reaching 100% prevalence at 30 days (17, 22). Catheter encrustations can also 
obstruct urine flow, promoting urine stagnation and bacterial replication. This 
process is mediated by urease-producing bacteria, which alkalinize the urine, 
precipitating hydroxyapatite or struvite crystals (22). Thus, Proteus spp., 
Providencia spp., Morganella morganii and Corynebacterium urealyticum are 
predominantly found, but Klebsiella spp., P. aeruginosa, Serratia spp. and 
Staphylococcus are too urease producers (in low level) and can mediate this 
process (17). 
 
e) Any urological condition associated to obstruction (exemplified in Figure 3 by 
hypothetical mechanism of formation of calcium oxalate (CaOx) stones by 
bacterial growth) increase the risk of UTI (18). 
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FIGURE 3 - Speculated mechanisms for bacterial contribution to calcium oxalate stones. (A) Figure key. (B) 
Bacteria bind to CaOx crystals that may provide a nidus for pyelonephritis or remain persist in a subclinical state (1) and 
bacterial communities form a biofilm (2). The biofilm results in crystal aggregation (3). (C) The bacterial enzymes citrate 
lyase splits citrate resulting in increased CaOx supersaturation (1). CaOx crystals form providing a key element of 
lithogenesis. (D) Bacteria bind to the urothelium (1) that results in secretion of innate immune proteins from recruited 
inflammatory cells (2) and urothelium (3). The innate immune proteins are incorporated as stone matrix proteins [reprinted 
from reference (36)]. 
 
Most kidney stones are composed primarily of CaOx (80%). Oxalobacter 
formigenes is a Gram-negative, anaerobic bacterium, present in a large proportion 
of the normal adult population (46-77%), which metabolizes oxalate (derived from 
both endogenous and exogenous sources) in the intestinal tract, and associated 
with a reduced risk for CaOx kidney stones (37). The absence of Oxalobacter 
formigenes could lead to increased absorption of dietary oxalate in the colon, and 
the subsequent increase in urinary oxalate that could favor the development of 
CaOx stones (37, 38). 
Data from previous studies show that patients with kidney stones and 
hyperoxaluria have a lower prevalence of Oxalobacter formigenes in the stool, that 
can be a potential risk factor for formation of CaOx stones (37, 38).  
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f) In older men, hypertrophy prostatic increases the urinary symptoms and urinary 
retention, predisposing to chronic prostatitis. This chronic inflammatory process 
can promote the formation of stones that store  bacteria, causing rUTI (22).  
 
g) Neurological conditions such as dementia, cerebrovascular disease, 
Alzheimer´s disease and Parkinson´s disease promote bladder and bowel 
incontinence and functional decline, affecting the innate defense mechanisms and 
increase the risk of UTI (18, 22).  
 
h) Patients with diabetes mellitus are at a high risk for UTIs, ASB and rUTI, because 
the hyperglycosuria promote bacterial growth (18, 35).  Abnormal glycosylation 
observed in this pathology can also affect the function of soluble glycoproteins in 
the urine, favoring the adherence by type-1 fimbriae of Uropathogenic Escherichia 
coli (UPEC) to the urothelial surface. Neutrophil and lymphocyte dysfunction found 
in diabetics may also compromise the elimination of bacteria from the urinary tract 
in the later stages of infection (35).   
 
i) In postmenopausal women, the estrogen deficiency has been associated with 
rUTI, cystoceles and urinary incontinence, promoting the ascending of bacteria to 
the urinary tract (18, 22). Estrogen deficiency impairs the beneficial effects of 
bacterial colonization of the vagina with Lactobacillus, which normally protect 
against growth of pathogenic bacteria (22).  
 
j) An increased incidence of different comorbidities is associated with aging. 
Moreover, impaired acquired cellular immunity occurred namely as a result of T-
cell dysfunction and blunted cytokine-mediated inflammatory response. Those 
dysfunctions are accentuated in the setting of diabetes, cancer, and autoimmune 
disorders (39). 
 
1.2.5. RECURRENT URINARY TRACT INFECTIONS  
rUTI are defined as two uncomplicated infections in a 6-month time period or three 
infections within a year (17, 21, 40). The probability that patients develop a second UTI 
within 6 months is 25%, and the possibility of recurrence over a 12-month period 
increases for 46% (40). 
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Even before the evidence of a resident urinary bacterial community in healthy individuals, 
it was evident that an independent inoculation of urinary tract would not totally explain the 
recurrence of UTI episodes (11, 12, 40). In fact, several studies demonstrated that  many 
rUTI episodes (>50%) involved bacterial strains genetically identical, being suggested the 
involvement of intracellular bacterial reservoirs within the bladder mucosa that would 
provide persistent urinary pathogens (21, 40).  
The UPEC strains, for example, can invade host epithelial cells, including superficial cells 
(umbrella cells) as well as intermediate and basal cells; enter to cytosol and rapidly 
multiply, forming a biofilm known as an intracellular bacterial community. The efflux of 
UPEC and exfoliation of infected superficial cells may promote the dissemination of UPEC 
within the urinary tract. The UPEC that remain in a dormant state can establish quiescent 
reservoirs, extremely difficult to eradicate with antibiotic therapy (Figure 4) (40). 
 
 
FIGURE 4 - Events that promote the establishment and recurrence of urinary tract infection [reprinted from 
reference (40)]. 
 
Recent findings have suggested that multiple factors, such as gene-gene and gene-
environmental interactions and their deregulation may predispose patients to rUTI. It is 
suspected that some genes may be associated with susceptibility to rUTI, in particular, 
HSPA1B, CXCR1/2, TLR2, TLR4 and TGF-β1 genes seem to be related with an alteration 
of the host response to UTIs (41). 
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1.2.6. NATURAL CONDITIONS PREVENTING URINARY TRACT INFECTION 
Several functional mechanisms, such as barrier effect, mucous production, regular 
bladder emptying, urinary microbiota, urine flow and some chemical characteristics of 
urine (Table 5) are involved in defense of the urinary tract against UTIs (42). 
 
TABLE 5 - Chemical characteristics of urine influencing urinary tract infections susceptibility [readapted from 
reference (42)]. 
Urine parameter UTI relevance 
pH Optimal bacterial growth in urine occurs between a pH 6-7. 
Urea High urea concentrations are associated with inhibition of bacterial growth 
Glucose Glucosuria can promote bacterial growth. 
Calcium Idiopathic hypercalciuria increases the risk of UTIs. 
Iron Increased iron promotes bacterial growth in urine. 
Osmolality Bacterial growth is inhibited when the urine osmolality is < 200mosm/L or > 1200 mosm/L 
 
Moreover, the cellular and humoral innate immunity have complementary functions in 
mediating response against UTIs (43).  
Cellular innate immunity and cell-associated receptors play an important role in defense 
against UTIs (41). The chemokines secreted by the infected mucosa promote the 
recruiting of neutrophils to the urinary tract. The bladder resident macrophages recruit 
both neutrophils and inflammatory monocytes to the bladder during acute UTI; the 
inflammatory monocytes induce the transmigration of neutrophils for bladder epithelium 
(44).  
An overgrowth of bacteria also is associated with the induction of a strong innate immune 
response determined by Toll-like receptor (TLR), activation and production of antimicrobial 
peptides (AMPs) (e.g. cathelicidin, α-defensins, β-defensins, hepcidin, ribonuclease 7), 
chemokines (e.g. CCL2, CXCL1, CXCL2) and cytokines (e.g. G-CSF or IL-17). The TLR4, 
TLR5 and TLR6 have a significant role, mediating proinflammatory response and 
leukocyte recruitment (Figure 5, 6) (42, 43, 45). Moreover, the epithelium and circulating 
leukocytes increase the production of AMPs (42). 
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FIGURE 5 - Innate immune mechanisms in the urinary tract. Microbes enter the urinary tract and encounter 
constitutively expressed AMPs that can inhibit attachment to the urothelium (A) or cause bacterial lysis (B). If bacteria attach 
to the urothelium, they can induce AMP production, which results in destruction of adherent bacteria (C). When bacteria 
bind and invade the urothelium, they can elicit the production of chemokines (D/E) that attract inflammatory cells across the 
urothelium (F). These cells control infection by phagocytosis (G) and secretion of intracellular AMPs (H) [reprinted from 
reference (32)]. 
 
 
FIGURE 6 - Signaling pathway of toll-like receptors in urinary tract infection. Activation of TLRs expressed on the cell 
membrane by a bacterial ligand sets in motion a series of processes that leads to the release of inflammatory chemokines, 
cytokines and AMPs [reprinted from reference (32)]. 
 
Humoral innate immunity also plays an effective role in UTI. This response is composed 
by complement cascade and soluble pattern recognition molecules such as collectins, 
ficolins, and pentraxins (e.g. PTX3). Soluble pattern recognition molecules are essential 
for elimination of bacteria by their opsonic activity, promoting the phagocytosis and 
maturation of the phagosome. Polymorphisms in PTX3 were associated with increased 
susceptibility to UTI in humans (43, 44).  
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1.2.7. ETIOLOGY OF URINARY TRACT INFECTIONS 
The most common organism causing UTI and ASB in both community and healthcare 
settings are E. coli, followed by other Enterobacteriaceae, such as Proteus mirabilis, 
Klebsiella and Providencia species. Gram-positive bacteria, such as methicillin resistant 
Staphylococcus aureus (MRSA) and Enterococcus, are less commonly isolated, however, 
are identified with increasing frequency in healthcare settings, associated with chronic 
indwelling catheters (Figure 7) (13, 19, 20, 26, 46).   Nevertheless, the prevalence of 
bacterial species isolated are different for each LTHF and countries (22, 47). In a cohort of 
LTHF residents in United States of America, E. coli was the predominant urinary 
pathogen, with a frequency of 53.6%. Other Enterobacteriaceae were also common, 
namely Proteus (14.6%), Klebsiella (13.9%) and Providencia (3.7%) (19, 22). Gram-
positive bacteria including Enterococcus and Staphylococcus accounted for 4.5% and 
4.1% of positive urine cultures, respectively. Another study conducted in 32 LTHF from 
Sweden, the E. coli also was the most common urinary pathogen isolated (69%), but the 
second most common was Klebsiella spp. (12%), followed by E. faecalis (8%) (48).  
In a national point study (2013) of prevalence of infection-acquired in hospital setting and 
antimicrobial use, covering 18258 patients distributed by 103 hospitals with different 
typologies (22.3% primary; 40.8% secondary; 22.3% tertiary and 12.6% specialized 
hospitals), the most common urinary pathogens isolated in UTIs were E. coli (31.4%), 
followed by Klebsiella spp. (16.3%), P. aeruginosa (11.6%) and Enterococcus spp. 
(10.2%) (24). A previous national point study, from 2012, involving 5150 residents living in 
232 continuing healthcare facilities, of which 82.5% corresponding to LMTHF, also 
demonstrated the dominance of E. coli, although in higher frequency (39.5%), followed by 
Klebsiella spp. (10%), P. mirabilis (9.5%), P. aeruginosa (6.3%) and S. aureus (5.8%) (6).  
The profile of the urinary pathogens causing UTIs in LMTHF patients, observed in these 
cohorts studies, resemble hospital-acquired UTIs more than the community-acquired (1, 
49, 50). Aforementioned LMTHF residents conditions (please see section 1.1) seem to 
justify the observed similarity to hospital-UTI pathogens profile (15, 19, 22, 49). 
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FIGURE 7 - The most common organisms isolated from urinary cultures in older adults [reprinted from reference 
(19)]. 
 
In noncatheterized patients or with short-term urinary catheter a single bacterium usually 
causes bacteriuria, and in 10% to 20% of cases is polymicrobial. In contrast, ASB is 
almost always polymicrobial in patients with chronic urinary catheter use. The etiology in 
these patients is dynamic because colonization by a specific bacterium is transient, with a 
mean duration of six weeks. E. coli is found in 18% to 35% of cases, followed by Proteus 
in 10% to 60%, Providencia in 24% to 60%, Enterococcus in 25%, Pseudomonas in 6% to 
20% and Enterobacter in 9% (22). 
 
1.2.7.1. ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE CLONES CAUSING UTI 
E. coli and K. pneumoniae have been the most frequent species causing UTI in patients 
from continuing healthcare facilities in Portugal (4, 24).  
In the last years several research studies unveiled major groups within these species 
associated with UTI and to clinically relevant antibiotic resistance mechanisms. The E. coli 
can be classified into four main phylogenetic groups and corresponding subgroups: A (A0, 
A1), B1, B2 (B22, B23) and D (D1, D2) (51, 52).  
Several studies have suggested a relationship between phylogeny and pathogenicity in 
this specie, with virulent extraintestinal strains belonging mainly to B2 and D phylogroups, 
and commensal strains to phylogenetic groups A and B1 (51, 53). However, recent 
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epidemiological data highlights the increasing identification of A and B1 E. coli involved in 
extraintestinal infections (51, 52). 
E. coli can be categorized into different pathotypes, depending on the site and type of 
infection: i) associated with enteric/diarrheal disease, such as enteropathogenic E. coli 
(EPEC), enterohaemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), 
enteroaggregative E. coli (EAEC), and diffusely adherent E. coli (DAEC) and ii) associate 
with extra-intestinal pathogenesis, such as UPEC, sepsis-associated E. coli (SEPEC), 
neonatal meningitis-associated E. coli (NEMEC) and avian pathogenic E. coli (APEC), 
which are generically defined as extra-intestinal pathogenic E. coli (ExPEC). UPEC are 
the mainly cause of community-acquired (70-95%) and nosocomial (50%) UTIs; however, 
the capacity of colonization and persistence in the urinary tract is depending of the variety 
of virulence factors (VFs) expressed by UPEC (51). 
ExPEC VFs can be grouped in adhesins, toxins, siderophores, capsule, protectins and 
miscellaneous factors according to their functions. Some of the most important virulence 
genes of UPEC strains associated with severe UTIs are aer that codified for aerobactin, 
pap that codified for P fimbriae, type 1 fimbriae,  afaI that codified for afimbrial adhesion I,  
hly that codified for hemolysin,  cnf 1 that codified for cytotoxic necrotizing factor 1, sfa 
that codified for S fimbriae, adhesins and fimbriae; however, other virulence genes such 
as kpsMT, ompT, usp, iroN, iha, set 1, astA, group II capsule synthesis; sfa/foc, S and 
F1C fimbriae; iutA, traT, serum resistance; and fimH, are known to be involved in 
pathogenicity of these strains. Previous studies reported that O1, O2, O4, O6, O7, O8, 
O15, O16, O18, O21, O22, O25, O75 and O83 serogroups are preferentially associated 
with UPEC strains (51, 54). 
Some UPEC are spread worldwide and are found in a variety of niches (human infections, 
healthy individuals, food and animals), such as the clone ST131 (B2), ST95 (B2), ST69 
(D) or ST648 (D), while others are more frequently found in clinical isolates, such as 
ST393 (D), ST405 (D) or ST38 (D) and ST73 (B2), ST155 (B1) and ST359 (B1), whereas 
some are frequently identified in animals, such as ST10, ST23 or ST410 clonal complexes 
(phylogenetic group A) (51). 
An example is the O25:H4-ST131 clone distributed by 103 hospitals that initially was 
associated with the pandemic spread of CTX-M-15 in clinical isolates, and now is highly 
disseminated in a variety of niches. This clone is responsible for severe extra-intestinal 
infections and amplification of a variety of ESBL types, such as other CTX-M, SHV, 
AmpC-types or KPC or NDM (51). 
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Within phylogenetic group D, clonal group A (CGA) and O15:K52:H1 clonal groups were 
initially linked with community-associated UTI outbreaks and now are spread worldwide. 
CGA was initially responsible for up to 50% of trimethoprim/sulfamethoxazole-resistant E. 
coli in women with uncomplicated cystitis and pyelonephritis in several states of USA, and 
has now spread worldwide. This clone belongs to ST69, and was associated with 
particular serogroups (O11, O17, O73 and O77) and occasionally produced ESBLs in 
different countries (TEM-type, CTX-M-15 or CTX-M-14). The O15:K52:H1 clone 
(belonging to ST393) was mostly associated with UTIs, but also others infections. This 
clone has been associated with ESBL production (mostly CTX-M-15 or CTX-M-14). 
Inserted in phylogenetic group D, the ST405 is an MDR clone linked to extra-intestinal 
infections and frequently associated with CTX-M-15 production, in several geographic 
regions (51). 
Besides B2 and D, E. coli clones belonging to phylogenetic groups A (ST10 and ST23) 
and B1 (ST359 and ST155) have also been increasingly related as ESBL producers 
(CTX-M-14, CTX-M-15) and linked to extra-intestinal infections, and particularly UTIs (51). 
K. pneumoniae is an opportunist nosocomial pathogen, with MDR strains generally 
associated with UTI and pneumonia and the highly virulent strains linked to invasive 
infections, such pyogenic liver abscesses, which is an emerging disease particularly 
frequent in Asian countries (55). K. pneumoniae complex suffered recently some 
restructuration's, with the redesignation of the 3 initially defined phylogroups (KpI, KpII and 
KpIII) as distinct species, namely, K. pneumoniae, K. quasipneumoniae, and K. variicola. 
K. pneumoniae is the most frequently detected in clinical isolates (56).  Recently, 157 
distinct K. pneumoniae phylogenetic lineages were depicted based on analysis of the core 
genome. Moreover, it was demonstrated that the ability to cause invasive community-
acquired infections or hospital acquired infections is not determined by lineage per se but 
may be associated with a specific virulence or antibiotic resistance gene profile acquired 
horizontally. Nevertheless, some particular lineages are mostly associated with MDR or 
hypervirulence (56). For instances, some clones have been linked to the worldwide 
amplification of certain ESBLs or carbapenemases: clone ST15 has been associated with 
the spread of CTX-M-15 in different European and Asian countries (57), whereas the 
ST258 clone has been involved in the worldwide spread of KPC enzymes; ST11 clone is 
also largely distributed in different continents and associated with the production of 
diverse ESBLs (mainly CTX-M) or carbapenemases (KPC, OXA-48, NDM, VIM) (52). 
 
CHAPTER 1 - INTRODUCTION  
23 
 
1.3. MANAGEMENT AND THERAPEUTIC RECOMMENDATIONS FOR URINARY TRACT 
INFECTIONS IN LONG AND MEDIUM-TERM HEALTHCARE FACILITIES 
UTIs treatment represents 30% to 60% of antibiotics used in LTHF (7, 22). In Portugal, 
48.5% of antibiotics prescribed in continuing healthcare facilities were used for UTIs 
treatment (1, 7). This extended use could be explained by application of different 
diagnostic criteria, the complexity in differ ASB of symptomatic UTI in LMTHF residents 
and inappropriate antibiotics use (22). 
In fact, inappropriate antibiotic use was reported in 40-75% of cases, particularly in 
nursing homes (13, 22). Moreover, the excessive use of antibiotics are associated with 
negative consequences, such as development of MDR bacteria (58), side effects (e.g. 
Clostridium difficile infection) and high healthcare costs (13, 18). 
Given the difficulty of the differential diagnosis between ASB and symptomatic UTI in 
LMTHF patients, the increasing resistance to antimicrobials and the high rate of 
prescription of antibiotics for UTI in this setting it is advisable the use of a facility-adapted 
protocol to guide diagnosis and antimicrobial selection for suspected UTI (Figure 8). This 
practice was applied in 22 LTHF in Canada and Idaho, where occurred a decreased by 
30% in rate of suspected UTI and the rate of antibiotic use decrease by 20% at 3 months, 
and these changes persisted at 12 months (22). 
 
FIGURE 8 - Modified diagnostic algorithm that was used to identify and manage urinary tract infections in our 
long-term healthcare facility, which had a higher incidence of urinary tract infections than the national average. 
This algorithm divides symptoms into major and minor according to the strength of evidence of their association with UTI in 
LTC facilities [reprinted from reference (22)]. 
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Empiric therapeutic of UTI in LMTHF patients should consider the clinical history (e.g. 
allergy history, renal clearance, comorbidities) of the patient, the local prescriptions 
patterns, the prevalence of antibiotic resistance in this setting and adverse effect profile 
associated (14, 22). 
The International Clinical Practice Guidelines, updated in 2010 by the Infections Diseases 
Society of America and the European Society for Microbiology and Infectious Diseases, 
recommend as first line for empirical therapy for treatment of uncomplicated cystitis the 
nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days, or 
trimethoprim/sulfamethoxazole 160/800 mg twice for 3 days (13); however, antibiotics with 
local resistance rates greater than 20% should only be used if a urinary culture with 
antimicrobial susceptibility testing is available (18, 19, 26, 58). 
The antibiotic therapy recommended by European Association of Urology (2015) for 
treatment of uncomplicated cystitis in females is the fosfomycin trometamol 3 g single 
dose, pivmecillinam 400 mg tid for 3 days, and nitrofurantoin macrocrystal 100 mg bid for 
5 days, when available. Most ESBL-producing E. coli are still susceptible to fosfomycin; 
however, in Spain was observed a parallel increase in community use of fosfomycin and 
resistance to fosfomycin in ESBL-producing E. coli. In males it is recommended a 
treatment with duration of at least 7 days, preferably with cotrimoxazole or a 
fluoroquinolone and in accordance with the susceptibility testing. In patients with renal 
insufficiency the choice of antibiotic may be influenced by the decreased renal excretion. 
Most antibiotics, however, have a wide therapeutic index. No adjustment of dose is 
necessary until glomerular filtration rate < 20 mL/min, except for antibiotics with 
nephrotoxic potential (e.g. aminoglycosides). Combination of loop diuretics (e.g. 
furosemide) and a cephalosporin is nephrotoxic. Nitrofurantoin and tetracyclines are 
contraindicated (17).  
Alternative antibiotics include trimethoprim alone or combined with a sulphonamide, and 
the fluoroquinolone class. Cotrimoxazole (160/800 mg bid for 3 days) or trimethoprim (200 
mg for 5 days).The Food and Drug Administration (FDA) have not recommend the use of 
fluoroquinolones for uncomplicated cystitis, which should be reserved for when there is no 
alternative treatment options (59). Fluoroquinolones are associated with several adverse 
effects including negative ecological effects and selection of resistance strains (17). 
Aminopenicillins (amoxicillin) are no longer recommended for empirical therapy because 
of the worldwide high rates of E. coli resistance. Aminopenicillins in combination with a 
betalactamase inhibitor such as ampicillin/sulbactam or amoxicillin/clavulanic acid and 
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oral cephalosporins are in general not so effective as short-term therapy and are not 
recommended for empirical therapy, but can be used in selected cases (17). 
In mild and moderate cases of pyelonephritis, the European Association of Urology (2015) 
recommended oral therapy for 10-14 days. A fluoroquinolone for 7-10 days can be 
recommended as first-line therapy if the resistance rate of E. coli is still < 10%. However, 
with increasing numbers of fluoroquinolone-resistant E. coli in the community the empirical 
use of fluoroquinolones is restricted. A third-generation oral cephalosporin could be an 
alternative. As result of increasing E. coli resistance rates >10%, the cotrimoxazole is not 
recommended for empirical therapy, but it can be used in case of sensitivity after 
confirmation through susceptibility testing. In communities with high rates of 
fluoroquinolone-resistant and ESBL-producing E. coli (> 10%), initial empirical therapy 
with an aminoglycoside or carbapenem has to be considered until susceptibility testing 
demonstrates that oral drugs can also be used (17). 
In patients with severe pyelonephritis and systemic symptoms (e.g. nausea, vomiting) it is 
not recommended oral medication, and it has to be treated initially with one of the 
following parenteral antibiotics, described in the Table 6. The recommendations for others 
therapeutic indications are also summarized in the Table 6 (17). 
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TABLE 6 - Summary of recommendations for antimicrobial therapy in urology [reprinted from reference (17)]. 
 
In Portugal, the recommendations adopted for treatment of UTIs are defined in guidelines 
elaborated by general direction of health, and were adjusted based in the 
recommendations of the International Clinical Practice Guidelines, updated in 2010 by the 
Infections Diseases Society of America and the European Society for Microbiology and 
Infectious Diseases for community-acquired UTIs (Table 7) (60). However, this guideline 
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does not consider that etiology and antimicrobial resistance pattern of urinary pathogens 
in LMTHF patients may differ from community-acquired UTIs, compromising the efficacy 
of antimicrobial therapeutic response. Moreover, we lack studies reporting the antibiotic 
susceptibility of isolates causing UTI in Portuguese LMTHF residents in order to 
appropriately support empirical therapy. 
TABLE 7 - Treatment recommended for therapeutic indication [adapted from reference (60)]. 
Population Antibiotics Dosage Duration 
Uncomplicated acute cystitis in 
female 
Nitrofurantoin 100 mg 6/6 hours 5 – 7 days
#
 
Fosfomycin 3000 mg/day 1 day 
Amoxicillin/clavulanic acid * 
625 mg (500 + 125 mg) 8/8 
hours 
5 – 7 days 
Pyelonephritis – mild to 
moderate cases 
Ceftriaxone followed by 
Cefuroxime 
1 gr IV or IM (1 take) 
500 mg 12/12 hours 
7 – 14 days 
Pyelonephritis – mild to 
moderate cases in patients 
intolerant to beta-lactams 
Levofloxacin 750 mg/day 5 days 
Pyelonephritis – severe cases 
(sepsis) 
Ceftriaxone 2 gr/day IV or IM 
Decision in 
hospital setting 
Pyelonephritis – severe cases 
in patients intolerant to beta-
lactams 
Gentamycin followed by 
antibiotic therapy directed by 
susceptibility testing 
5 mg/Kg/day IV 
Decision in 
hospital setting 
Asymptomatic bacteriuria in 
candidates to resection of the 
prostate 
Ceftriaxone 
1 gr IV, 12/12 hours (start 
24-48 hours before surgery) 
3 – 6 days 
* Alternative antibiotic therapy, if antibiotics above are unavailable or contraindicated 
#
 In males, in absence of prostatitis, the therapy should have a duration of 7-10 days 
 
1.4. β-LACTAMASES WITH CLINICAL RELEVANCE IN THE MAIN ETIOLOGIC AGENTS OF 
URINARY TRACT INFECTIONS  
ESBLs and carbapenemase producers are the MDR pathogens causing UTI of special 
concerns in healthcare institutions. In this section, ESBLs and carbapenemase features 
will be addressed, unveiling their epidemiology and clinical relevance (61, 62).  
β-lactamase production constitutes the most important mechanism of resistance to β-
lactam antibiotics among Enterobacteriaceae (63). 
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The classification of β-lactamase enzymes have been based on the chemical constitution 
of their active site (serine or zinc) or their hydrolytic profiles over distinct β-lactams 
(penicillins, cephalosporins, monobactams, carbapenems) and their inactivation by 
classical β-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam) (64, 65). 
They are: i) the Ambler molecular classification and ii) the Bush-Jacoby-Medeiros 
functional classification: 
i. Ambler classification: divides β-lactamases into four major classes (A, B, C and 
D) based on amino acid sequence homology. In this classification, β-lactamases of 
class A, C and D are serine-β-lactamases (serine residue in the active site), 
whereas class B enzymes are metallo-β-lactamases (MBLs) (zinc atom in the active 
site) (64). 
 
ii. Bush-Jacoby-Medeiros classification: divides β-lactamases into four main 
groups, based on functional similarities (substrate and inhibitor profile) (65): 
a) Group 1/Ambler class C: includes cephalosporinases that are encoded in the 
chromosome and/or in plasmids, and that are not inhibited by the classical β-
lactamase inhibitors (65). 
 
b) Group 2/Ambler classes A and D: represent a heterogeneous group of β-
lactamases that includes penicillinases, cephalosporinases, oxacillinases and 
carbapenemases, which are inhibited by the classical β-lactamase inhibitors. 
Different subgroups are further considered, one of which includes ESBLs (2be 
subgroup) (65). 
 
c) Group 3/ Ambler class B: includes MBLs, which are enzymes with a high 
hydrolytic activity over carbapenems and that are inhibited by chelating agents, 
such as ethylenediamine tetraacetic acid. They are not inhibited by classical β-
lactamase inhibitors and do not hydrolyze monobactams (65). 
 
d) Group 4: includes enzymes that are not inhibited by classical β-lactamase 
inhibitors and that cannot be classified in the other groups (65). 
β-lactamases are intrinsically produced by particular species (e.g. AmpC in Citrobacter 
freundii or SHV-1 in K. pneumoniae) or they could be acquired throughout horizontal 
transfer, commonly associated with plasmids. ESBLs, qAmpCs and carbapenemases are 
-lactamases that have been acquired by several species with ability to inactivate several 
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β-lactam antibiotics relevant in the treatment of human infections. The emergence and 
dissemination of Enterobacteriaceae producing ESBLs, qAmpCs and/or carbapenemases 
in different settings represent a major concern in many countries (66-70), with serious 
implications for both public health and infection control practices (71).    
The molecular epidemiology of ESBL- or carbapenemase-producing Enterobacteriaceae 
has been worldwide described in detail, but there are few recent data about 
epidemiological features of these β-lactamases-producing Enterobacteriaceae in 
Portuguese LMTHF. Moreover, few data is available for qAmpC epidemiology in clinical 
setting (66-69, 71). 
 
1.4.1.     EXTENDED-SPECTRUM β-LACTAMASES-PRODUCING ENTEROBACTERIACEAE  
ESBLs have the ability to hydrolyze penicillins, first-, second-, third- and four-generation 
cephalosporins, and monobactams, but not cephamycins and carbapenems, and are 
inhibited by β-lactamase classical inhibitors such as clavulanic acid, tazobactam or 
sulbactam (72-74). Most ESBLs belong to the Amber class A of β-lactamases. Certain 
class D OXA-derived enzymes are also included within ESBLs (73).  
The genes coding for ESBLs (blaESBL)s are plasmid-mediated and the most commonly 
mechanism of resistance described among Enterobacteriaceae species (63). Clonal 
and/or plasmid dissemination are frequently associated with the evolution of bla genes, 
resulting in new ESBL variants (50). 
ESBLs can be classified into different families, according to their amino acid sequence. 
ESBLs belonging to the TEM, SHV or CTX-M types are the most frequently reported 
among Enterobacteriaceae and are worldwide disseminated, whereas OXA, PER, GES, 
IBC and VEB seem to be confined to specific geographic areas (75).  
TEM and SHV ESBLs were the most frequently identified in nosocomial K. pneumoniae 
and Enterobacter spp. isolates (75, 76). To date, more than 200 TEM and 150 SHV 
variants have been identified (77), reflecting the rapid emergence and evolution of these 
enzymes under the selective pressure of antibiotic (78). 
Whereas most of variants TEM and SHV have been only sporadically described and/or 
confined to specific geographic areas, others have a global distribution throughout 
different settings (76, 78). For example, TEM-24 has been mainly associated with 
nosocomial outbreaks in different Europeans countries (Spain, Portugal, Belgium and 
CHAPTER 1 - INTRODUCTION  
 
30 
 
France), while SHV-12 and TEM-52 are widely disseminated in the different settings. 
SHV-2, SHV-5 and TEM-10 are also widespread but mainly in the hospital setting (72). 
More recently, CTX-M enzymes have become the most prevalent ESBL family in both the 
nosocomial and community settings, being mainly identified in E. coli isolates (72). They 
evolved from genes that have been captured by mobile genetic elements (MGE), such as 
ISEcp1 or ISCR1, from the chromosome of different species of Kluyvera spp. (53, 79). 
These enzymes hydrolysis preferentially the cefotaxime than ceftazidime. However, a few 
variants have afterwards been described with ability to hydrolyze both cephalosporins (53, 
79, 80). 
Nowadays, CTX-M β-lactamases include more than 130 different enzymes (77) that are 
clustered into six groups according to their amino acid identities, namely the CTX-M-1, 
CTX-M-2, CTX-M-8, CTX-M-9, CTX-M-25 and CTX-M-45 groups (53, 79). CTX-M-14 and 
CTX-M-15 are worldwide disseminated in both community and hospital settings (Figure 9) 
(74). 
 
 
FIGURE 9 - Frequency of overlapping extended-spectrum β-lactamase– and plasmid-encoded AmpC genes in 
Escherichia coli isolates from various sources, Sweden. Data for leafy greens were excluded because there were 
only two isolates (both blaCTX-M-1) from this source [reprinted from reference (74)]. 
 
Other CTX-M enzymes are confined to particular geographic regions, such as CTX-M-2 
(Canada, South America, Israel and Japan), CTX-M-3 (Eastern Europe, South Africa and 
CHAPTER 1 - INTRODUCTION  
31 
 
China), and CTX-M-9 (Spain, United Kingdom and Japan). CTX-M-1 and CTX-M-32 are 
frequently identified among nosocomial isolates, mostly in Mediterranean countries, but 
also among animals and environmental bacteria (72). In Portugal the CTX-M-1, CTX-M-15 
and CTX-M-32 are frequently observed (Figure 10) (81). 
 
 
FIGURE 10 - Distribution of CTX-M enzymes in Europe [reprinted from reference (81)]. 
 
The major clone associated to expansion of ESBL-producing Enterobacteriaceae is the 
ST131 in E. coli, which has been responsible for the worldwide spread of CTX-M-15 (75, 
82), however, this clone has also been detected encoding other ESBLs (CTX-M-1, -2, -3, - 
9, -14; SHV-12) or carbapenemases (NDM-1), highlighting its potential for diversification. 
Other E. coli clones belonging to group D (ST69, ST393, ST405) are also disseminated 
among different hosts, often causing urinary tract infections and producing ESBLs (mainly 
CTX-M), cephamycinases (qAmpCs), carbapenemases (NDM) and/or methylases (AmrA, 
RmtB). In addition, A and B1 E. coli (clonal complexes such as CC10 or CC23) are also 
identified among ESBL-producing isolates in nosocomial setting (72). 
The ST15 K. pneumoniae clone has been associated with the spread of CTX-M-15 in 
different European and Asian countries (57, 72). The ST11 K. pneumoniae clone are also 
extensively distributed in different continents and linked to the production of diverse 
ESBLs (mainly CTX-M) or carbapenemases (KPC, OXA-48, NDM, VIM) (72). Outbreaks 
of ESBL-producing Enterobacteriaceae other than E. coli or K. pneumoniae isolates have 
also been described, but in most cases they seem to be of local significance. An epidemic 
E. aerogenes strain encoding TEM-24 has been detected in different European countries 
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(80), although it was able to acquire other ESBLs (SHV-12, SHV-5, TEM-20) (83). Other 
reports included outbreaks of E. cloacae (CTX-M-9), P. mirabilis (CTX-M-2), S. 
marcescens (CTX-M-3) and K. oxytoca (TEM-7) in different countries (72, 80). 
ESBL production  constitutes one of the most relevant antibiotic resistance mechanism 
(84) and has been observed mostly in Enterobacteriaceae, mainly in E. coli and K. 
pneumoniae (85); however, all other clinically-relevant Enterobacteriaceae species could 
produce  these β-lactamases (73, 86). The level of expression and properties of β-
lactamases, and the co-presence of other resistance mechanisms (others β-lactamases, 
increased activity of efflux pumps, modifications in membrane permeability) can result in 
the large variety of resistance phenotypes observed among ESBL-producer isolates (73). 
ESBL-producers isolates are commonly resistant to different antimicrobial category 
besides β-lactamases, including fluoroquinolones, trimetoprim/sulfametoxazol and 
aminoglycosides, which contribute to the selection and persistence of MDR ESBL strains 
and plasmids in both clinical and community settings (75).  
Fluoroquinolone resistance is being increasingly reported among Enterobacteriaceae 
(mainly in E. coli and K. pneumoniae) (87). It has been associated with mutations at DNA 
gyrase (GyrA) and/or topoisomerase IV (ParC) chromosomal genes and/or with the 
emergence of plasmid-mediated quinolone resistance (PMQRs) genes (75, 87-90). 
PMQRs encode Qnr proteins (e.g. QnrA, QnrB, QnrC, QnrD and QnrS) protecting target 
enzymes, acetylases that affect the activity of some fluoroquinolones and 
aminoglycosides [AAC(6’)-Ib-cr], and/or efflux systems that pump fluoroquinolones out of 
the bacterial cell (QepA and OqxAB) (87, 90). Some PMQR mechanisms have been 
associated with the production of particular ESBL-types, such as AAC(6’)-Ib-cr and CTX-
M-15, QnrA and CTX-M-9 group enzymes, or QnrS1 and VIM-1 (72). 
Portugal is one of the European countries with higher rates of ESBL-producers in clinical 
setting (84, 91), leading frequently to therapeutic failures (92). Long-term hospitalizations 
leading to nosocomial infections and exposure to antibiotics, increase the risk of 
acquisition of ESBL-producing isolates (93). 
In Portugal, it is unknown the extent of these enzymes in urinary isolates from LMTHF. A 
national point study (2012) conducted in continuing healthcare (integrating different 
typologies) demonstrated that resistance rate to third-generation cephalosporin was 
24.7%, not differing between ESBL or AmpC β-lactamases for all type of infections (1).  
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1.4.2.     ACQUIRED AMPC-β-LACTAMASES-PRODUCING ENTEROBACTERIACEAE  
Chromosomal-encoded AmpC β-lactamases were initially identified in some 
Enterobacteriaceae species (e.g. E. coli, Shigella spp., Citrobacter spp., Serratia spp., 
Hafnia alvei, Morganella spp., Enterobacter spp.), Acinetobacter spp., Pseudomonas spp., 
and other genus (94), however, AmpC β-lactamases encoded by plasmid-mediated genes 
were also observed in different species, including some that naturally lack the 
chromosomal blaAmpC genes, such as Klebsiella spp., P. mirabilis and Salmonella spp. (94, 
95). Eight AmpC-types are recognized: ACC, ACT, CFE, DHA, FOX, LAT, MIR, MOX 
(96). 
There are several natural lineages of qAmpCs described in species or genus, namely the 
Enterobacter group (MIR-1, ACT-1), the C. freundii group (LAT and most of the CMY 
types), the M. morganii group (DHA-1 and DHA-2), the H. alvei group (ACC-1), the 
Aeromonas group (CYM-1, CMY-8, CMY-9, FOX, MOX) and the A. baumannii Group 
(ABA) (52, 95). More recently was identified a new qAmpC (CDA-1) in a Cedecea davisae 
strain.  Phylogenetic analysis demonstrated a high  similarity to the chromosome-encoded 
β-lactamase from Enterobacter (52). 
AmpC β-lactamases were positioned in the Ambler C class. These enzymes are resistant 
to β-lactamase inhibitors (clavulanic acid) and hydrolyze penicillins, first-generation 
cephalosporins, and depending on the enzyme, second-generation cephalosporins 
including cephamycins (e.g. cefoxitin, cefotetan) and third-generation cephalosporins to a 
lesser extent (73, 97). The AmpC-type (ACC-1) exceptionally not confer resistance to 
cephamycins and is inhibited by cefoxitin (94). 
Enterobacteriaceae are divided in different groups, according with resistance phenotypes 
conferred by AmpC:  
1- Group 0 (Enterobacteriaceae lacking AmpC): Salmonella spp. and P. mirabilis 
lack natural AmpC β-lactamase genes, being intrinsically susceptible to penicillins, 
aztreonam, cephalosporins and carbapenems (94). 
 
2-  Group 1 [producing intrinsic (“wild-type”)]: exhibit also susceptibility phenotype 
(e.g. E. coli and Shigella spp.) (98), despite they produce very low levels of a non-
inducible (lacks an ampR gene) chromosomal AmpC-type cephalosporinase (94). 
 
3- Group 2 (low-level cephalosporinases): In many Enterobacteriaceae species (e.g. 
E. cloacae, E. aerogenes, C. freundii, Providencia spp., M. morganii, H. alvei, 
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Serratia spp., Pantoeae agglomerans), the chromosomal AmpC expression is 
inducible by β-lactams (strong inducers include cefoxitin, imipenem, and clavulanic 
acid) (94, 98). The low-level cephalosporinases comprises resistance to 
penicillins/β-lactamase inhibitor combinations, and first-generation cephalosporins. 
They can be divided in sub-groups according with their behavior to cefuroxime and 
cefoxitin: (i) species usually susceptible both antibiotics (H. alvei, P. rettgeri, P. 
stuartii, and P. agglomerans); (ii) species more resistant to cefoxitin than 
cefuroxime (E. cloacae, E. aerogenes, and C. freundii); and (iii) species more 
resistant to cefuroxime than cefoxitin (S. marcescens and M. morganii) (98). 
 
4- Group 3 (high-level cephalosporinases): characterized by more or less resistance 
to penicillins (except to amdinocillin or temocillin), first-, second-, at least one third-
generation cephalosporins and aztreonam.  Fourth-generation cephalosporins are 
usually more active. The synergy test (phenotypic method) to detect ESBL 
expression with clavulanic acid and third-, fourth-generation cephalosporins or 
aztreonam is negative. Cephamycins are inactive except for ACC-1 in the specie 
H. alvei. Resistance conferred by AmpCs to different β-lactams can be partially or 
totally restored in the presence of cloxacillin (AmpC β-lactamase inhibitor) (98). 
The hyperproduction of AmpC in species with inducible expression of this enzyme 
(e.g. Enterobacter spp., C. freundii, Providencia spp., and S. marcescens) is 
thought to be derived from the action of the LysR-type transcriptional regulator 
AmpR, whereas in E. coli the high-level cephalosporinases is mainly due to 
mutations in the promoter or attenuator region and/or gene duplication (52, 98). 
 
5- Group 4 (acquired AmpC β-lactamases): in this group, the high-level 
cephalosporinase phenotype can result from acquisition of a plasmid encoded 
blaAmpC gene (qAmpC) (52).  
The qAmpC most dominant and globally widespread is CMY-2, reported not only in E. coli 
isolates but also among Salmonella spp. from different clinical settings (52, 69). DHA-1 is 
the second most prevalent qAmpC, and has been particularly detected among K. 
pneumoniae recovered from hospitals. Other qAmpC-types have been only sporadically 
reported. Most of qAmpC producers other than Salmonella have been associated with 
urinary tract infections. The relevance of clonal expansion, plasmid dissemination or both 
mechanisms in the spread of qAmpCs varies with the bacterial species and/or the 
qAmpC-type (52).  
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Studies involving multiple clinical settings, revealed CMY-2 as the dominant qAmpC, with 
exception of a longitudinal Portuguese study (2002-2013) performed in isolates of different 
settings [community (53%), hospital (47%)]  reporting the dominance of DHA-1 among 
Enterobacteriaceae isolates in different clinical settings, mostly in K. pneumoniae isolates, 
representing 96% between 2002 and 2008 versus 55% in 2009 to 2013, while CMY-2 was 
mostly recovered in E. coli isolates, representing 4% between 2002 and 2008 versus 45% 
in 2009 to 2013 (99). 
The characterization of CMY-2 producing E. coli population revealed a high clonal 
diversity and the absence of a predominant clone, however, have been detected some 
widespread lineages of E. coli belonging to phylogenetic group B2 (ST95, ST131), D 
(ST69, ST393, ST405, ST648), and A e B1 clonal complexes (ST10, ST155, ST168, 
ST448) (52). 
The dissemination of DHA-1, in Portugal, was associated with ST11-K. pneumoniae clone 
(belonging to clonal group CG258), despite it had been more commonly linked to the 
worldwide spread of different carbapenemases (KPC-2/-3; VIM-1/-4; NDM-1; OXA-48/-
245) or ESBLs (SHV-5/-12; CTX-M-3/-15; SFO-1) (52, 67). In Portugal, 48% of DHA-
producing K. pneumoniae isolates belonged to ST11, obtained from several clinical 
institutions (hospital and community) at different regions (99). 
Caniça et al. (2014) evaluated a group of 124 Enterobacteriaceae isolates resistant to 
third generation cephalosporins, collected in distinct healthcare facilities of different 
Portuguese regions, and identified 86.3% (107/124) ESBLs producers, revealing a 
diversity of class A β-lactamases from different families, like TEM, SHV and GES, as well 
as detected class C enzymes like plasmid-mediated AmpC β-lactamases (PMAβs, DHA-
1, and CMY-2) and chromosomal AmpCs in Enterobacter and Citrobacter spp. (100). 
Although qAmpCs are normally encoded by genes located in plasmids, the dissemination 
of blaqAmpC between the same or different Enterobacteriaceae species are also associated 
with the horizontal transmission of other MGEs. The plasmids more frequently identified 
were IncI1 and IncA/C; these have been associated with spread of blaCMY-2 among 
members of the family Enterobacteriaceae (mostly clonally unrelated E. coli or Salmonella 
spp.) recovered from clinical or non-clinical settings (52). Recently, IncA/C plasmids 
carrying blaCMY-4 or blaCMY-16 have acquired other antibiotic resistance genes, such as 
genes coding for carbapenemases (blaNDM-1, blaVIM-4, blaOXA-48, blaOXA-204) and/or quinolone 
resistance proteins (qnrA6), ESBLs (blaCTX-M-15, blaPER-1), 16S rRNA methylases (armA), 
and fosfomycin resistance (fosA3). Diverse plasmid families associated to blaDHA-1 were 
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identified in K. pneumoniae, such as IncL/M, IncHI2, IncR and IncFIA groups. Plasmids 
carrying qAmpCs genes (blaCMY-2-like, blaDHA-1-like, blaFOX-like, blaACT-1, blaACT-2, blaACT-7, blaACT-
16) often carry multiple other β-lactam resistance genes, including genes coding for ESBLs 
(TEM-type, SHV-type, CTX-M-type, PER-1, OXA-1) and/or carbapenemases (OXA-48/-
162/-204, VIM-1/-4, IMP-1/-4, NDM-1, KPC-2, CARB-2/PSE-1) (52, 101, 102), as well as  
resistance elements to non-β-lactam antibiotics, such as aminoglycosides (e.g. armA, 
rmtB, rmtC), fluoroquinolones [e.g. qnrA, qnrB, qnrS, aac(6′)-Ib-cr], and sulfonamides (e.g. 
sul1), amongst others (52, 99). 
 
1.4.3.     CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE 
Carbapenemases are β-lactamases that have the ability to hydrolyze almost all β-lactams 
(including carbapenems), and most of them are not inhibited by the classical β-lactamase 
inhibitors (79). However, the decrease susceptibility to carbapenems in 
Enterobacteriaceae can be caused by ESBLs or AmpC enzymes combined with 
decreased permeability due to alteration or down-regulation of porins (e.g. inactivation of 
genes coding for outer membrane proteins, with decrease production of OmpK35 and 
OmpK36 in K. pneumoniae) (44, 58, 60, 63). Ertapenem is the carbapenem most affected 
by this mechanism (58). 
 
The carbapenemases are distributed in all Ambler classes, although Ambler classes A, B 
and D includes the most epidemiologically relevant (73, 103-105). Class A and B enzymes 
usually confer higher resistance levels to carbapenems; variants have been described 
with low-level resistance profiles, which hinder their identification by susceptibility tests in 
the laboratory (106, 107). 
These enzymes have emerged as a consequence of the increasing use of carbapenems 
in infections caused by ESBL-producing Enterobateriaceae (76, 108). The most frequent 
belong to class A (KPCs), class B (MBLs) and class D (OXAs) β-lactamases (73). 
The KPCs are clinically and epidemiologically the most important enzyme among 
Enterobacteriaceae species, associated with prolonged in-hospital stay (109), conferring 
resistance to penicillins, to first-, second- and third-generation cephalosporins, 
carbapenems and monobactams, and being inhibited by clavulanic acid (106). KPCs have 
been considered endemic in the United States of America, Israel, Greece and Italy, and 
outbreaks have also been reported in China, Brazil and several European countries. 
These enzymes have also been identified in other Enterobacteriaceae species such as E. 
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coli, Enterobacter spp. and K. oxytoca. The ST258 clone has been involved in the 
worldwide spread of KPC enzymes (72). 
The MBLs hydrolyze all β- lactams except aztreonam, and are inhibited by chelator agents 
such as ethylenediamine tetraacetic acid, but not by clavulanic acid. These enzymes are 
encoded by genes located at the chromosome of several Gram-positive and Gram-
negative species (e.g. Bacillus spp., P. aeruginosa, Stenotrophomonas maltophilia, 
Aeromonas spp.), or by plasmid-encoded genes acquired by horizontal gene transfer 
(mainly in K. pneumoniae and E. coli) (110). The most common plasmid-mediated MBLs 
detected among Enterobacteriaceae species are VIM, IMP and NDM-1 types (79, 106, 
110). MBL-producing Enterobacteriaceae have been described worldwide, with VIM-1 and 
VIM-2 being the most disseminated variants, mainly in K. pneumoniae (79, 106, 108). 
VIM-producing Enterobacteriaceae are endemic in Greece (Spain, Italy, Denmark, 
Hungary, Brazil, Argentina), whereas IMP-types are more prevalent in Asian countries 
(72). NDM-1 was identified for the first time in a K. pneumoniae isolate from an Indian 
patient previously hospitalized in New Delhi Sweden in 2008 (111), and have been 
imported into Europe, Asia, North America and Australia by those who have travelled or 
were hospitalized in the India (112). These β-lactamases have been identified in different 
Enterobacteriaceae species (mainly K. pneumoniae and E. coli, but also Enterobacter 
spp., C. freundii, M. morganii and Providencia spp.) (72). 
The OXAs are a heterogeneous group of β-lactamases with activity over amino- and 
ureido-penicillins, oxacillin, cloxacillin and carbapenems, which are inhibited by sodium 
chloride (113). These enzymes are frequently reported among A. baumanni and P. 
aeruginosa (OXA-23, OXA-24, OXA-51, OXA-58), but members of this group (most 
frequently OXA-48) are increasingly being reported among Enterobacteriaceae species 
(113). OXA-48 was firstly identified in a K. pneumoniae isolate in Turkey (72), and more 
recently have disseminated in the Middle East and North Africa, with several outbreaks 
occurring in Europe (United Kingdom, Belgium, France, Spain and The Netherlands) (79, 
106, 114). Some OXA-48-like variants (e.g. OXA-163, OXA-181) have also been 
identified, differing from OXA-48 by a few amino acid substitutions or deletions (114). 
Carbapenems are considered first-line therapy for infection by MDR Enterobacteriaceae; 
however, the increasing emergence of carbapenemases have demonstrated higher 
mortality rates in patients infected with carbapenem-resistant Enterobacteriaceae, due to 
reduced therapeutic options (115).  
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In Portugal, is unknown the extent of carbapenemases in urinary isolates from LMTHF, 
but a national point study (2012) conducted in continuing healthcare (integrating different 
typologies) revealed that resistance rate to third-generation cephalosporin and 
carbapenemes was 6.5% for all type of infections (1). 
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2.1. STATEMENT OF OBJECTIVES 
UTIs are known to be one of the most common bacterial infections in both community and 
hospital settings. 
In recent years with the ageing of the population and the expansion of LMTHF, placed at 
an interface between these settings, a new ecological niche with particular conditions for 
transmission of bacterial pathogens and/or MDR bacteria emerged. 
UTIs are an increasing challenge in LMTHF due to the high occurrence rates, the frequent 
resident’s comorbidities, the diversity of etiologic agents, the diagnostic difficulties, as well 
as the growing antibiotic resistance rates. 
The rapid emergence or increase of resistance to critically important antibiotics, together 
with the dynamics of species and/or clones with variable antibiotic resistance profiles, 
determine the need of a continuous monitoring of etiologic agents and antibiotic 
resistance profiles in this setting in order to appropriately assist empiric treatment of UTI. 
 
 
 
 
 
This study focused on the following specific aims: 
1. To evaluate in LMTHF residents with UTI, the occurrence and trends of etiologic 
agents.  
2. To determine the antimicrobial susceptibility rates of the different uropathogens 
identified and the frequency of MDR pathogens. 
 
3. To analyze the trends in antibiotic resistance rates for the most common 
uropathogens. 
 
The general aim of the present study was to provide comprehensive and longitudinal 
data on the etiologic agents of UTI in LMTHF patients and their corresponding 
antimicrobial susceptibility rates, in order to contribute to improve infection control 
practices and appropriately support empirical treatment. 
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4. To determine the frequency of clinically important antibiotic resistance 
mechanisms (ESBLs and carbapenemases) in major pathogens responsible for 
UTI. 
 
2.2. OUTLINE OF THE DISSERTATION 
The findings answering the specifics aims of the dissertation are presented in a research 
article format, and will be subject to subsequent submission to a scientific journal: 
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OBJECTIVE: The goal of this study is to evaluate the etiology of urinary tract infections (UTIs) and the antimicrobial 
resistance patterns of uropathogens identified among patients from a Portuguese long and medium-term 
healthcare facility unit. 
 
MATERIALS AND METHODS: A retrospective analysis of bacterial pathogens responsible for UTIs and their 
corresponding antimicrobial resistance patterns identified among a total of six hundred and ninety-one urine 
samples from patients institutionalized in Santa Casa da Misericórdia de Vila do Conde was conducted between 
November 2010 and August 2015. Antimicrobial susceptibility rates and antibiotic resistance mechanisms were 
detected using antibiotic panels of the commercially available automated system MicroScan® (autoSCAN® 
System; BECKMAN COULTER). 
 
RESULTS: A total of 471 urine samples (68.2%) were positive for bacterial growth, where 512 uropathogens were 
identified. Escherichia coli was the most prevalent species (38.5%), followed by Klebsiella pneumoniae (26.8%), 
Proteus spp. (8.6%) and Pseudomonas aeruginosa (7.2%), whilst Enterococcus faecalis (4.3%) were the most 
frequent Gram-positive bacteria. Multidrug resistance patterns were frequently observed (n=242/512; 47.3%), with 
the high rates registered for K. pneumoniae (59.1%). The highest antimicrobial resistance rates were observed for 
penicillins (61.4%-97.5%), followed by fluoroquinolones (43.5%-55.0%) and trimethoprim/sulfamethoxazole 
(49.6%). On the other hand, nitrofurantoin, cefoxitin, amikacin, piperacillin/tazobactam, carbapenems and 
glycopeptides were the most active antibiotics (2.0%-10.0%). Amongst the most frequent uropathogens identified 
(E. coli and K. pneumoniae), the antibiotic resistance rates to extended-spectrum cephalosporins, 
trimethoprim/sulfamethoxazole and ciprofloxacin increased substantially, especially after 2011, whereas imipenem, 
nitrofurantoin and fosfomycin remained stable during the whole period studied (<6.0%). ESBL producers were 
detected in 24.1% (n=101/419) of Enterobacteriaceae isolates, being of note the recent increase of ESBL-
producing K. pneumoniae (reaching 72.2% in 2015). Two ESBL-producing K. pneumoniae strains were 
simultaneously carbapenemase-producers. Statistically significant differences were as not observed between 
gender and incidence of ESBL-producing strains (P=0.524). 
 
CONCLUSIONS: We found alarming rates and trends of MDR pathogens causing UTIs in the period studied, alerting 
for the need of further surveillance in these settings. Whilst some antibiotics commonly used for empirical treatment 
proved to be of little utility. Nitrofurantoin and fosfomycin were considered the most appropriate antimicrobials. 
Thus, empirical antibiotic prescription in long and medium-term healthcare facilities should be guided by and 
adjusted to local data.  
 
Tel. 220 428 580 
Fax: 222 003 977 
E-mail address: lpeixe@ff.up.pt 
 
 KEYWORDS 
Antimicrobial resistance, Extended-spectrum β-lactamases, Multidrug-resistance, Uropathogens 
 
1. INTRODUCTION 
 
Urinary tract infections (UTIs) are one of the most common 
healthcare-associated infections and the incidence of 
multidrug-resistant (MDR) bacteria causing UTIs is an 
increasing Public Health problem in different settings such as 
hospitals, the community and long-term care facilities, including 
in Portugal (1-7). 
The long and medium-term healthcare facilities (LMTHF) are an 
intermediate setting between the community and the hospital 
settings, where the frequent flow to acute care hospitals and 
the close proximity between residents increase the risk of 
infections and favors the acquisition and transmission of MDR 
bacteria (8, 9). In fact, the resident’s population of LMTHF is 
generally old, with frequent comorbidities (e.g. diabetes, spinal 
cord injury, stroke, dementia, urinary or faecal incontinence) 
and present several risk factors for developing UTIs, including 
advanced age, impaired mobility, chronic illness, 
immunosuppression, use of urinary catheters, and 
inappropriate antimicrobial use favoring colonization with MDR 
bacteria during hospitalization (9-12).  
In Portugal, the etiology and antibiotic resistance patterns of the 
most common pathogens causing UTIs in either hospital and 
community settings is well known (4, 5, 7, 13,14) but the 
information regarding the epidemiology in LMTHF is scarce and 
based mostly on a point-prevalence study (15, 16), where data 
on antimicrobial resistance rates of urinary pathogens from 
LMTHF is missing. 
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The aim of the present study was to evaluate the etiology of 
UTIs and the antimicrobial resistance patterns of the 
corresponding uropathogens in patients from a Portuguese 
LMTHF unit, between November 2010 and August 2015. 
 
2. MATERIALS AND METHODS 
 
2.1. STUDY DESIGN 
A retrospective analysis of the etiology and antimicrobial 
resistance patterns of bacterial pathogens causing UTIs in the 
Santa Casa da Misericórdia de Vila do Conde was performed 
between November 2010 and August 2015. This unit consists 
on a LMTHF of 40 beds, located in the North of Portugal, and 
data was collected at the Clinical Analysis Laboratory. 
For UTIs patients, demographic data including age and sex of 
the resident and date of sample collection was recorded. 
 
2.2. COLLECTION OF SAMPLES AND ISOLATES 
IDENTIFICATION 
Six hundred ninety-one urine samples were analyzed in the 
study period (2010-2015). Only samples with pyuria (5–10 
white blood cells per high power field or more) and bacteriuria 
(≥ 105 CFU/mL), following clinical symptoms (mild fever, 
dysuria, pollakiuria, frequency and urgency, hematuria, cloudy 
urine or strong odor, suprapubic pain, new or worsening of 
incontinence, or deterioration in functional or mental status) 
were considered as positive.  
Urine samples with polymorphic bacterial growth (growth of 
three or more bacterial species) were discarded. Worked up 
clean-catch midstream morning urine specimens were collected 
using sterile containers, according to standard procedures. 
Urine samples were inoculated aseptically on CLED and 
MacConkey agar using calibrated wire loops (1µl) and then 
incubated aerobically at 37ºC for 24 to 48 hours. Uropathogens 
identified in positive cultures, were identified by Gram-staining 
and standard biochemical procedures using commercial 
systems MicroScan® (autoSCAN® System; BECKMAN 
COULTER). 
 
2.3. ANTIMICROBIAL SUSCEPTIBILITY TESTING AND 
ANTIBIOTIC RESISTANCE MECHANISMS 
Antimicrobial susceptibility patterns and antibiotic resistance 
mechanisms were inferred using antibiotic panels of the 
commercial automated system MicroScan® (autoSCAN® 
System; BECKMAN COULTER) specific for 
Enterobacteriaceae (Urine Combo 69), Gram-negative non-
Enterobacteriaceae (Neg Non Entero Combo 71) and Gram-
positive cocci (Pos Combo 42). Antibiotic susceptibility tests 
were determined and interpreted using guidelines and clinical 
breakpoints established by the Clinical and Laboratory 
Standards Institute (CLSI) (17) and the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST; 
http://www.eucast.org/). 
The antibiotics tested for Enterobacteriaceae were ampicillin, 
amoxicillin/clavulanic acid, piperacillin/tazobactam, cefazolin, 
cefoxitin, cefuroxime, cefotaxime, ceftazidime, cefepime, 
ertapenem, imipenem, meropenem, norfloxacin, ciprofloxacin, 
levofloxacin, amikacin, gentamicin, tobramycin, fosfomycin, 
nitrofurantoin and trimethoprim/sulfamethoxazole.  
Gram-negative bacteria non-Enterobacteriaceae were tested 
against piperacillin/tazobactam, cefotaxime, ceftazidime, 
cefepime, aztreonam, norfloxacin, ciprofloxacin, levofloxacin, 
imipenem, meropenem, doripenem, amikacin, gentamicin, 
tobramycin, colistin, fosfomycin and 
trimethoprim/sulfamethoxazole.  
For Gram-positive bacteria, the panel of antibiotics comprises 
penicillin G, ampicillin, amoxicillin/clavulanic acid, ciprofloxacin, 
levofloxacin, gentamicin, tobramycin, teicoplanin, vancomycin, 
rifampin, trimethoprim/sulfamethoxazole, fosfomycin and 
nitrofurantoin. 
For all Enterobacteriaceae isolates, the production of extended-
spectrum β-lactamase (ESBL) was confirmed by using 
ceftazidime and ceftazidime/clavulanic acid and the cefotaxime 
and cefotaxime/clavulanic acid combinations, in the automated 
system MicroScan® (autoSCAN® System; BECKMAN 
COULTER), according to criteria established by the EUCAST. 
Carbapenemase production was confirmed by the Blue-Carba 
test (18). 
 
2.4. STATISTICAL ANALYSIS 
Demographic data, urinary pathogens and antibiotics 
resistance patterns obtained were analyzed using the Statistical 
Package for Social Sciences (SPSS) version 23.0. Frequencies 
and percentages were generated for categorical variables, such 
as sex, age, urinary pathogens genus or/species and rate of 
isolation. 
The genus or/species of bacteria more frequently isolated were 
introduced in multiple correspondence analyses to detect 
possible correlations with antimicrobial resistance patterns. 
Chi-square test was applied to detect association between 
ESBL and sex. A P-value of ≤0.05 was considered statistically 
significant. 
 
2.5. ETHICAL CONSIDERATIONS 
Ethical approval was obtained by the Ethics Committee of 
Santa Casa da Misericórdia de Vila do Conde. Resident’s 
privacy was protected by de-identification of records. All the 
data obtained during the study were kept confidential, and used 
only for the purpose of this study. 
 
3. RESULTS 
 
3.1. ETIOLOGY OF BACTERIAL UROPATHOGENS 
A total of 471 cultures were positive (n=471/691; 68.2%), 430 of 
them (91.3%) had monomorphic bacterial growth, while 41 
(8.7%) presented two different bacterial species, corresponding 
to a total of 512 uropathogens isolated and analyzed.  
The patient’s age ranged from 28 years to 98 years, with mean 
age of 75±12 years (median 78 years). A total of 414 
(n=414/691; 59.9%) urine samples were from female patients 
whereas 277 (n=277/691; 40.1%) were from males, 
corresponding to a male to female ratio of 1:1.49. The rate of 
positive samples was similar between females and males 
(Table 1). 
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          Table 1 Gender distribution of patients with positive samples with UTI. 
 
Demographic 
characteristics 
Positive No.  
(%) 
Negative No. 
(%) 
Total No.  
(%) 
Gender 
Male 184 (66.4) 93 (33.6) 277 (100.0) 
Female 287 (69.3) 127 (30.7) 414 (100.0) 
Total 471 (68.2) 220 (31.8) 691 (100.0) 
 
Most of the UTIs were caused by Gram-negative bacteria 
(92.2%), while Gram-positive bacteria were much less identified 
(7.8%). Escherichia coli was the most common uropathogen 
isolated, followed by Klebsiella pneumoniae, Proteus spp. and 
Pseudomonas aeruginosa, whilst Enterococcus faecalis was 
the most frequent Gram-positive cocci. E. coli and K. 
pneumoniae were isolated more frequently in female (29.5-
42.3%) than male’s patients (22.5%-32.5%), while the 
frequency of isolation of Acinetobacter spp., P. aeruginosa and 
Staphylococci was higher in males (4.0%-9.0%) than females 
(0.3%-6.1%) (Table 2). 
 
In general, E. coli was more frequently involved in UTIs than K. 
pneumoniae, although similar rates were observed in 2012, 
2013 and 2015 (Figure 1). 
 
 
Figure 1 Incidence of Escherichia coli and Klebsiella pneumoniae causing UTI (November 
2010 - August 2015. 
 
3.2. OVERALL ANTIBIOTIC RESISTANCE PATTERNS  
Multidrug resistance patterns were frequently observed among 
urinary pathogens (n=242/512; 47.3%), especially for 
Providencia spp. (92.9%), Acinetobacter spp. (86.7%), 
Morganella morganii (75.0%) and P. aeruginosa (62.2%). It is 
of note that the incidence of MDR E. coli (39.1%) was lower 
compared to that of K. pneumoniae (59.1%). 
When the overall antimicrobial resistance rates of all bacterial 
uropathogens are considered, the highest scores were 
obtained for penicillins (61.4%-97.5%), followed by 
fluoroquinolones (43.5%-55.0%) and 
trimethoprim/sulfamethoxazole (49.6%). Nitrofurantoin, 
cefoxitin, amikacin, piperacillin/tazobactam, carbapenems and 
glycopeptides showed lower resistance rates (2.0%-10.0%) 
(Table 3). Nevertheless, these patterns vary according to the 
particular bacterial families, genera or species, as described 
below.  
 Almost all Enterobacteriaceae isolates demonstrated high 
resistance rates to fluoroquinolones, ampicillin and 
trimethoprim/sulfamethoxazole (0.0%-71.4%) whilst the 
opposite was observed for amikacin, piperacillin/tazobactam, 
nitrofurantoin and carbapenems (0.0%-12.5%). Acinetobacter 
spp. isolates showed high resistance rates to all antibiotics (≥ 
40%), including to carbapenems. P. aeruginosa was frequently 
resistant to fluoroquinolones, 3rd and 4th generation 
cephalosporins (36.1%-90.5%) whereas the most active 
antibiotics were meropenem, followed by doripenem, colistin, 
amikacin, aztreonam and imipenem (5.3%-18.9%).  
All Gram-positive cocci, with exception of E. faecalis, were 
resistant to fluoroquinolones and ampicillin (100%). On the 
other hand, Staphylococci and E. faecalis demonstrated high 
susceptibility to glycopeptides (0.0%-7.1%) and E. faecalis to 
nitrofurantoin (0.0%). Despite the uncertainty on its clinical 
efficacy, the trimethoprim/sulfamethoxazole was tested against 
Enterococci revealing a high resistance rate (100%). All S. 
aureus were susceptible to fosfomycin and 80.0% were 
susceptible for nitrofurantoin.  
 
3.3. TRENDS IN ANTIMICROBIAL RESISTANCE RATES FOR 
THE MOST COMMON UROPATHOGENS 
The resistance rates to the most frequent therapeutic options 
observed for E. coli and K. pneumoniae in the study period are 
represented in Figure 2A and Figure 2B, respectively.  
In E. coli, resistance rates to cefuroxime and cefotaxime have 
been increasing since 2011, whereas resistance to 
trimethoprim/sulfamethoxazole and ciprofloxacin both peaked 
during 2011 (>50%) and lowered subsequently (especially 
ciprofloxacin) till 2015. Resistance to imipenem, nitrofurantoin 
and fosfomycin remained stable during the whole period 
studied (< 6.0%).  
Regarding K. pneumoniae, resistance rates to almost all 
antibiotics increased after 2011, with the exception of 
imipenem, which remained at <6.0% in 2015.  
Resistance to carbapenems was observed in three K. 
pneumoniae isolates from 2014 to 2015; two of them were 
concomitantly producers of ESBL and carbapenemase (KPC-
type, data not shown), whereas the other was negative for 
carbapenemase production. 
Table 2 Uropathogens from urine samples of patients with UTI. 
 
 
Microorganism 
Female Males Total 
No. % No. % No. % 
Escherichia coli 132 42.3 65 32.5 197 38.5 
Klebsiella pneumoniae 92 29.5 45 22.5 137 26.8 
Proteus spp. 25 8.0 19 9.5 44 8.6 
Providencia stuartii 7 2.2 7 3.5 14 2.7 
Citrobacter spp. 6 1.9 3 1.5 9 1.8 
Morganella morganii 1 0.3 7 3.5 8 1.6 
Other Enterobacteriaceae 4 1.3 6 3.0 10 2.0 
Acinetobacter spp. 4 1.3 11 5.5 15 2.9 
Pseudomonas 
aeruginosa 
19 6.1 18 9.0 37 7.2 
Other no fermentative 
gram-negative 
0 0.0 1 0.5 1 0.2 
Staphylococcus aureus 0 0.0 5 2.5 5 1.0 
Coagulase negative 
Staphylococcus 
1 0.3 3 1.5 4 0.8 
Enterococcus faecalis 15 4.8 7 3.5 22 4.3 
Enterococcus faecium 6 1.9 3 1.5 9 1.8 
Total 312 100 200 100 512 100 
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Table 3 Antimicrobial resistance rates of isolates causing UTI  
Antimicrobial category 
(a) 
Antimicrobial agent (a) 
E.  coli 
K. 
pneumoniae 
Proteus 
spp. 
P. stuartii 
Citrobacter 
spp. 
M. 
morganii 
Other 
Enterobacteriaceae 
Acinetobacter 
spp. 
P. 
aeruginosa 
Other no 
fermentative 
gram-
negative 
S. aureus CNS E. faecalis E. faecium 
Total 
antimicrobial 
resistance 
rate 
T R % T R % T R % T R % T R % T R % T R % T R % T R % T R % T R % T R % T R % T R % R (%) 
Aminoglycosides 
Amikacin (b) 63 3.2 38 2.6 11 0.0 5 0.0 1 0.0 3 0.0 3 0.0 5 40.0 33 15.2 1 100.0 - - - - - - - - 11 (6.7%) 
Gentamicin 196 17.9 137 46.7 44 11.4 - - 9 22.2 8 37.5 10 20.0 15 80.0 37 37.8 1 100.0 5 20.0 4 50.0 - - - - 141 (30.2%) 
Tobramycin 196 18.9 137 52.6 44 2.3 - - 9 22.2 8 25.0 10 20.0 15 73.3 37 21.6 1 0.0 1 100.0 1 100.0 - - - - 137 (29.8%) 
Ansamycins Rifampicin - - - - - - - - - - - - - - - - - - - - - - - - 15 6.7 8 75.0 7 (30.4%) 
Antipseudomonal 
penicillins + 
β-lactamase inibitors 
Piperacillin/ 
tazobactam 
196 3.6 137 6.6 44 0.0 14 0.0 9 0.0 8 0.0 10 0.0 - - 37 27.0 1 0.0 - - - - - - - - 26 (5.7%) 
Carbapenems 
Ertapenem (b) 62 0.0 38a 7.9 11 0.0 5 0.0 1 0.0 3 0.0 3 0.0 - - - - - - - - - - - - - - 3 (2.4%) 
Imipenem 196 0.0 137 1.4 44 0.0 14 0.0 9 0.0 8 12.5 10 0.0 5 100.0 37 18.9 1 0.0 - - - - - - - - 15 (3.3%) 
Meropenem (b) 61 0.0 38a 5.3 11 0.0 5 0.0 1 0.0 3 0.0 3 0.0 3 66.7 19 5.3 - - - - - - - - - - 5 (3.5%) 
Doripenem - - - - - - - - - - - - - - - - 16 6.3 - - - - - - - - - - 1 (6.3%) 
1st and 2nd generation 
cephalosporins 
Cefazolin (c) 134 20.9 99 50.5 30 6.7 - - - - - - 1 0.0 - - - - - - - - - - - - - - 80 (30.3%) 
Cefuroxime 195 19.0 137 51.1 41 48.8 9 77.8 8 100.0 - - 9 55.6 - - - - - - - - - - - - - - 128 (32.1%) 
3rd and 4th 
generation 
cephalosporins 
Cefotaxime 195 16.4 137 47.4 44 6.8 14 7.1 9 11.1 5 10.0 10 20.0 15 93.3 21 90.5 - - - - - - - - - - 138 (30.7%) 
Ceftazidime 196 16.3 137 48.9 44 4.5 14 7.1 9 22.2 8 50.0 10 40.0 15 66.7 37 40.5 1 0.0 - - - - - - - - 137 (29.1%) 
Cefepime 135 14.8 99 43.4 33 3.0 9 0.0 8 0.0 5 20.0 7 0.0 12 91.7 36 36.1 1 0.0 - - - - - - - - 89 (25.8%) 
Cephamycins Cefoxitin 195 1.0 137 6.6 44 4.5 14 0.0 - - 8 37.5 2 0.0 - - - - - - - - - - - - - - 16 (4.0%) 
Fluoroquinolones 
Ciprofloxacin 196 38.8 137 47.4 44 34.1 14 92.9 9 22.2 8 62.5 10 10.0 15 86.7 37 59.5 1 100.0 5 100.0 4 100.0 22 50.0 9 100.0 242 (47.4%) 
Levofloxacin (b) 62 33.9 38 63.2 11 45.5 5 100.0 1 100.0 3 66.7 3 0.0 3 66.7 33 60.6 1 100.0 5 100.0 4 100.0 22 50.0 9 100.0 110 (55.0%) 
Norfloxacin 194 40.7 137 48.2 44 31.8 14 85.7 9 22.2 8 75.0 10 10.0 - - 5 60.0 - - - - - - - - - - 183 (43.5%) 
Folate pathway 
inhibitors 
Trimethoprim/ 
Sulfamethoxazole 
196 42.3 137 62.8 44 47.7 14 71.4 9 22.2 8 50.0 10 10.0 15 46.7 - - - - 5 0.0 4 25.0 6 100.0 2 100.0 223 (49.6%) 
Glycopeptides 
Teicoplanin - - - - - - - - - - - - - - - - - - - - 5 0.0 4 0.0 21 4.5 9 22.2 3 (7.5%) 
Vancomycin - - - - - - - - - - - - - - - - - - - - 5 0.0 4 0.0 14 7.1 7 28.6 3 (10.0%) 
Monobactams Aztreonam 2 50.0 - - - - - - - - - - - - - - 32 18.8 1 0.0 - - - - - - - - 7 (20.0%) 
Nitrofurans Nitrofurantoin 194 0.5 - - - - - - 9 11.1 - - 8 0.0 - - - - - - 5 20.0 4 0.0 22 0.0 9 22.2 5 (2.0%) 
Penicillins 
Ampicillin 195 68.2 - - 41 31.7 - - - - - - - - - - - - - - 5 100.0 4 100.0 8 0.0 2 100.0 156 (61.4%) 
Penicillin G - - - - - - - - - - - - - - - - - - - - 5 100.0 4 100.0 22 95.5 9 100.0 39 (97.5%) 
Penicillins + 
β-lactamase inibitors 
Amoxicillin/ 
clavulanic acid 
195 14.4 137 29.2 44 9.1 - - - - - - 2 0.0 - - - - - - 1 100.0 1 100.0 - - - - 74 (19.5%) 
Phosphonic acids Fosfomycin 195 2.6 137 17.5 44 38.6 14 92.9 9 11.1 8 87.5 10 20.0 - - 20 85.0 - - 5 0.0 4 25.0 - - - - 87 (19.5%) 
Polymyxins Colistin - - - - - - - - - - - - - - - - 32 12.5 - - - - - - - - - - 4 (12.5%) 
(T) Total number of bacterial isolates tested against each antimicrobial agent; (R %) Percentage of bacterial isolates resistant to antimicrobial agent; (-) Antimicrobial not tested 
(a) Exclusion of species with intrinsic resistance to antimicrobial agents or categories 
(b) Amikacin, ertapenem, meropenem and levofloxacin were tested from January 2014 
(c) Cefazolin was tested between November 2010 and January 2014 
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Figure 2 Temporal patterns of resistance to selected antibiotics for A) Escherichia coli and B) 
Klebsiella pneumoniae, between November 2010 and August 2015. Y-axis represents 
resistance in percentage of bacterial isolates for year. Aug (amoxicillin/ clavulanic acid); Cft 
(cefotaxime); Crm (cefuroxime); Cp (ciprofloxacin); Fos (fosfomycin); Gm (gentamicin); Imp 
(imipenem); Fd (nitrofurantoin); T/S (trimethoprim/sulfamethoxazole). 
 
The presence of ESBLs was detected frequently among 
Enterobacteriaceae isolates (n=101/419; 24.1%), 
corresponding mostly to K. pneumoniae (n=64), E. coli (n=32), 
M. morganii (n=3), P. vulgaris (n=1) and E. cloacae (n=1). It is 
of interest to highlight that the rate of ESBL among K. 
pneumoniae isolates is higher than that of E. coli during the 
whole period analyzed (Figure 3). Moreover, a notable increase 
in the rate of ESBL-producing K. pneumoniae was observed 
more recently (from 43.3% in 2013 to 72.2% in 2015) whereas 
the rates of ESBL-producing E. coli remained between 11.2% 
and 22.2% during the study period. Statistically significant 
differences were not observed between the incidence of ESBL-
producing strains and gender (P=0.524). 
 
 
Figure 3 Distribution of the two main ESBL-producing species (%): evolution from November 
2010 to August 2015. 
 
All ESBL-producing E. coli and K. pneumoniae were resistant 
to ampicillin, cefazolin, cefuroxime, cefotaxime, ceftazidime and 
cefepime. Most of these isolates have high resistance rates to 
gentamicin, tobramycin, trimethoprim/sulfamethoxazole 
fluoroquinolones, and amoxicillin/clavulanic acid (34.4%-100%). 
These isolates showed the highest susceptibility rates to 
carbapenems, nitrofurantoin, fosfomycin, cefoxitin, amikacin 
and piperacillin/tazobactam (0.0%-14.1%) (Table 4). 
 
Table 4 Antimicrobial resistance rates of the two main ESBL-producing species. 
Antimicrobial 
category 
Antimicrobial agent 
E.  coli 
K. 
pneumoniae 
T R % T R % 
Aminoglycosides 
Amikacin (a) 13 7.7 22 4.5 
Gentamicin 32 53.1 64 89.1 
Tobramycin 32 62.5 64 92.2 
Antipseudomonal 
penicillins + 
β-lactamase 
inibitors 
Piperacillin/ 
tazobactam 
32 9.4 64 9.4 
Carbapenems 
Ertapenem (a) 13 0.0 22 13.6 
Imipenem 32 0.0 64 3.1 
Meropenem (a) 12 0.0 22 9.1 
Cephamycins Cefoxitin 32 0.0 64 6.3 
Fluoroquinolones 
Ciprofloxacin 32 90.6 64 79.7 
Levofloxacin (a) 12 100.0 22 95.5 
Norfloxacin 31 90.3 64 78.1 
Folate pathway 
inhibitors 
Trimethoprim/ 
sulfamethoxazole 
32 65.6 64 96.9 
Nitrofurans Nitrofurantoin 31 0.0 - - 
Penicillins + 
β-lactamase 
inibitors 
Amoxicillin/ 
clavulanic acid 
32 34.4 64 46.9 
Phosphonic acids Fosfomycin 31 3.2 64 14.1 
(T) Total number of bacterial isolates tested against each antimicrobial agent; (R %) 
Percentage of bacterial isolates resistant to antimicrobial agent; (-) Antimicrobial not 
tested 
(a) Amikacin, ertapenem, meropenem and levofloxacin were tested from January 2014 
 
 
4. DISCUSSION 
This study provides systematic data about the urinary bacterial 
pathogens responsible for UTIs and their antibiotic resistance 
patterns during a five-year period in a Portuguese LMTHF unit, 
providing a framework for appropriate guidance and 
prescription. 
The species distribution of our sample (the most common 
bacteria identified were E. coli and K. pneumoniae) are in 
accordance with data from surveillance reports available in the 
country in this setting (15, 16). Nevertheless, it is of interest to 
highlight the higher incidence of K. pneumoniae in our 
population (26.8%) than that reported in previous studies (9, 
15), which is in accordance with the increasing involvement of 
K. pneumoniae isolates in nosocomial infections (19). 
In our study, 47.3% of clinical isolates exhibited MDR patterns. 
This rate is similar to that observed in bacteria responsible for 
hospital- and long-term care facilities-acquired UTIs and higher 
than that commonly observed among pathogens causing 
community acquired UTIs (9, 10, 20). Indeed, the high-level of 
consumption of antibiotics may be responsible for this 
resistance (15, 16), particularly for fluoroquinolones (3, 6). The 
resistance rates observed for penicillins, first, second and third 
generation cephalosporins, fluoroquinolones, gentamicin, 
tobramycin and trimethoprim/sulfamethoxazole in this study is 
remarkable, particularly among Enterobacteriaceae. 
In our study, the incidence of ESBL producers (24.1%) is 
similar to that obtained in the national surveillance report 
considering long-term care facilities (16). Considering the age 
of the patients in this setting (median 78 years), the high 
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incidence of ESBL-producing isolates is in accordance with 
previous studies showing that age over 65 years old is a risk 
factor for β-lactamase-mediated resistance to oxyimino-β-
lactams in patients infected with enterobacteria (9, 21, 22). In 
accordance with previous studies in Portugal or other European 
countries, K. pneumoniae (63.4%) was the main species 
identified, followed by E. coli (31.7%) (4, 5, 10, 21, 23, 24). In 
these isolates, besides extended-spectrum β-lactams 
resistance, the co-resistance profiles observed for other 
antibiotic classes (fluoroquinolones, 
trimethoprim/sulfamethoxazole, gentamicin, tobramycin and 
amoxicillin/clavulanic acid) is particularly problematic in UTI and 
a long-term care setting since it limits therapeutic options and 
empirical antibiotic choices (20). In fact, the use of antibiotics 
with antibiotic resistance rates exceeding 10-20% is associated 
with an increased risk of treatment failure and selection of 
antibiotic resistant strains (25, 26).  
Conversely, the highest susceptibility rates were found for 
carbapenems, nitrofurantoin, fosfomycin, cefoxitin, amikacin 
and piperacillin/tazobactam. However, it is of interest to 
highlight the increased resistance to fosfomycin observed for 
ESBL-producing K. pneumoniae (14.1%) comparatively with E. 
coli (3.2%). This is worrisome because this antibiotic is 
increasingly used to treat UTIs caused by ESBL-producing 
strains (25, 27), and an acquired fosfomycin resistance gene 
(fosA3) was already detected in a clinical isolate in Portugal, 
alerting for the risk of further transmission (28).  
In Portugal, the treatment of UTIs in long-term care settings 
units is based in guidelines issued by the General Direction of 
Health for community-acquired urinary infections that do not 
take into account the differences in the epidemiology and 
susceptibility patterns of urinary pathogens in the different 
contexts. For this reason, it is necessary to adequate UTI 
treatment recommendations in these long-term care settings to 
the evolving epidemiology and changing bacterial susceptibility 
in order to optimize antibiotic prescription and subsequently 
clinical outcomes in institutionalized patients (20, 29). 
Considering the high prevalence of MDR isolates in this study, 
(and particularly of ESBL-producers), and since the efficacy of 
amoxicillin/clavulanic acid in the treatment of UTIs caused by 
these isolates has not been well-established (25), the 
nitrofurantoin and fosfomycin seem to be reasonable 
alternatives for the treatment of uncomplicated UTIs. While the 
nitrofurantoin requires longer courses of therapy and its 
therapeutic efficacy decreases in patients with compromised 
renal function, the fosfomycin is a satisfactory alternative 
because of its single-dose treatment, prolonged post-antibiotic 
effect and reduced secondary effects (25). Both antibiotics are 
not recommended for complicated or upper UTI (25, 30). The 
fluoroquinolones should be reserved for other than acute 
cystitis or as an alternative when these agents cannot be used 
(2, 31). 
As control the transmission of MDR isolates it is important to: i) 
notify the identification of MDR isolates by the laboratory to the 
healthcare facilities units; ii) to identify reservoirs of MDR 
bacteria in different healthcare settings; iii) to sign and notify 
MDR carriers especially when they are transferred to other 
healthcare institutions as well as when they are admitted in our 
unit; iv) to adopt barrier precautions for colonized and infected 
patients (antiseptic hand-washing, wearing gloves and gown) 
and isolation or cohorting when possible. 
  
5. CONCLUSION 
In conclusion, we found alarming rates and trends of MDR 
pathogens implicated in UTIs among patients from a long-term 
care facility in Portugal, alerting for the need of further 
surveillance in these settings. The antibiotic resistance patterns 
observed (nitrofurantoin and fosfomycin were considered the 
most appropriate antimicrobials) suggest that empirical 
antibiotic prescription needs to be adjusted to local data.  
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The LMTHF are an intermediate setting between the community and the hospital settings, 
with a marked expansion in recent years. Different LMTHF aspects and resident’s 
conditions enhance the possibility of infection acquisition namely by MDR bacteria. 
Although UTIs are common infections in LMTHF, information regarding the uropathogens 
epidemiology in Portuguese LMTHF is scarce and corresponding data on antimicrobial 
resistance rates is missing, highlighting the opportunity and relevance of the present 
study. 
 
Overall, the results of this dissertation conducted to the following general CONCLUSION: 
 
This study alerts for the increasing rates of MDR among etiologic agents causing 
UTIs in patients institutionalized in a LMTHF in Portugal, and highlights the need 
to adapt empirical treatment choices and infection control practices to local data. 
 
Particular conclusions are summarized as follows: 
- Gram-negative bacteria (92.2%, especially E. coli and K. pneumoniae) were the 
most prevalent uropathogens identified all over the period analyzed, which is in 
line with the species distribution observed among urinary pathogens from the 
hospital setting; 
 
- High antibiotic resistance rates were observed for β-lactams (penicillins, first-, 
second- and third-generation cephalosporins), fluoroquinolones and 
trimethoprim/sulfamethoxazole, whereas nitrofurantoin, fosfomycin, cefoxitin, 
amikacin, piperacillin/tazobactam, carbapenems and glycopeptides were the most 
active antibiotics; 
 
- The MDR patterns frequently observed (47.3%, especially among 
Enterobacteriaceae, Acinetobacter spp., and P. aeruginosa) reduce significantly 
the treatment options for these urinary pathogens and suggest that these settings 
seem to act as reservoirs of MDR bacteria and need to be further surveyed; 
 
- The increasing antibiotic resistance rates observed amongst the most common 
uropathogens (E. coli and K. pneumoniae) is worrying, where the recent 
extraordinary increase of MDR K. pneumoniae isolates deserves to be highlighted; 
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- The high and increasing occurrence of ESBLs among Enterobacteriaceae is 
alarming (especially for K. pneumoniae) and compromises almost all therapeutic 
options available for empirical treatment, being imipenem, nitrofurantoin or 
fosfomycin the most viable therapeutic options; 
 
- From this point of view, it is necessary that the empirical antibiotics regimen of 
UTIs-acquired in long and medium-term healthcare facilities be adjusted according 
to local data. 
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